- Occurrence and transmission potential of asymptomatic and 1
- presymptomatic SARS-CoV-2 infections: update of a living 2
- systematic review and meta-analysis 3
- 4

Diana Buitrago-Garcia*1,2 5

- Aziz Mert Ipekci*1 6
- Leonie Heron^{*1} 7
- 8 Hira Imeri¹
- Lucia Araujo-Chaveron^{3,4} 9
- 10 Ingrid Arevalo-Rodriguez⁵
- Agustín Ciapponi⁶ 11
- 12 Muge Cevik⁷
- Anthony Hauser¹ 13
- 14 Muhammad Irfanul Alam³
- 15 Kaspar Meili⁸
- 16 Eric A. Meyerowitz⁹
- Nirmala Prajapati¹⁰ 17
- Xueting Qiu¹¹ 18
- Aaron Richterman¹² 19
- 20 William Gildardo Robles-Rodríguez¹³
- Shabnam Thapa¹⁴ 21
- Ivan Zhelyazkov¹⁵ 22
- 23 Georgia Salanti¹
- 24 Nicola Low¹
- 25
- * These authors contributed equally to this work 26 27 28 29 30 31 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 32

- 33 1. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
- 34 2. Graduate School of Health Sciences, University of Bern, Bern, Switzerland
- 35 3. EHESP French School of Public Health La Plaine St Denis, Rennes, France
- 36 4. Institut Pasteur, Paris, France
- 37 5. Clinical Biostatistics Unit, Hospital Universitario Ramon y Cajal, IRYCIS, CIBER of
- 38 Epidemiology and Public Health, Madrid, Spain
- 39 6. Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina
- 40 7. Division of Infection and Global Health Research, School of Medicine, University of St.
- 41 Andrews, Fife, Scotland, United Kingdom
- 42 8. Department of Epidemiology and Global Health, Umeå University, Umeå, Sweden
- 43 9. Division of Infectious Diseases, Montefiore Medical Center, Bronx, New York, United States of
- 44 America
- 45 10. Université Paris-Saclay, Paris, France
- 46 11. Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard TH Chan
- 47 School of Public Health, Boston, United States of America
- 48 12. Division of Infectious Diseases, University of Pennsylvania, Philadelphia, United States of
- 49 America
- 50 13. Fundación Universitaria de Ciencias de la Salud. Bogotá, Colombia.
- 51 14. Manchester Centre for Health Economics, University of Manchester, Manchester, United
- 52 Kingdom
- 53 15. University of Sheffield, Sheffield, United Kingdom
- 54
- 55 Word counts: Abstract, 468; main text 4945; 2 tables; 3 figures; 191 references
- 56 Supplementary material: 2 text files; 5 tables; 5 figures; 1 checklist; 2 appendices
- 57 Corresponding author: <u>nicola.low@ispm.unibe.ch</u>

58 ABSTRACT

59 BACKGROUND

- 60 Debate about the level of asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-
- 61 CoV-2) infection continues. The amount of evidence is increasing and study designs have changed
- 62 over time. We updated a living systematic review to address three questions: (1) Amongst people who
- 63 become infected with SARS-CoV-2, what proportion does not experience symptoms at all during
- 64 their infection? (2) What is the infectiousness of asymptomatic and presymptomatic, compared with
- 65 symptomatic, SARS-CoV-2 infection? (3) What proportion of SARS-CoV-2 transmission in a
- 66 population is accounted for by people who are asymptomatic or presymptomatic?

67 METHODS AND FINDINGS

The protocol was first published on 1 April 2020 and last updated on 18 June 2021. We searched

69 PubMed, Embase, bioRxiv and medRxiv, aggregated in a database of SARS-CoV-2 literature, most

recently on 6 July 2021. Studies of people with PCR-diagnosed SARS-CoV-2, which documented

- symptom status at the beginning and end of follow-up, or mathematical modelling studies were
- 72 included. Studies restricted to people already diagnosed, of single individuals or families, or without

raise sufficient follow-up were excluded. One reviewer extracted data and a second verified the extraction,

74 with disagreement resolved by discussion or a third reviewer. Risk of bias in empirical studies was

assessed with a bespoke checklist and modelling studies with a published checklist. All data syntheses

76 were done using random effects models. Review question (1): We included 130 studies.

77 Heterogeneity was high so we did not estimate a mean proportion of asymptomatic infections overall

78 (interquartile range 14-50%, prediction interval 2-90%), or in 84 studies based on screening of

defined populations (interquartile range 20-65%, prediction interval 4-94%). In 46 studies based on

80 contact or outbreak investigations, the summary proportion asymptomatic was 19% (95% CI 15-25%,

- 81 prediction interval 2-70%). (2) The secondary attack rate in contacts of people with asymptomatic
- 82 infection compared with symptomatic infection was 0.32 (95% CI 0.16-0.64, prediction interval 0.11-
- 83 0-95, 8 studies). (3) In 13 modelling studies fit to data, the proportion of all SARS-CoV-2
- 84 transmission from presymptomatic individuals was higher than from asymptomatic individuals.
- 85 Limitations of the evidence include high heterogeneity and high risks of selection and information

- 86 bias in studies that were not designed to measure persistently asymptomatic infection, and limited information about variants of concern or in people who have been vaccinated. 87 CONCLUSIONS 88 Based on studies published up to July 2021, most SARS-CoV-2 infections were not persistently 89 90 asymptomatic and asymptomatic infections were less infectious than symptomatic infections. 91 Summary estimates from meta-analysis may be misleading when variability between studies is 92 extreme and prediction intervals should be presented. Future studies should determine the 93 asymptomatic proportion of SARS-CoV-2 infections caused by variants of concern and in people with 94 immunity following vaccination or previous infection. Without prospective longitudinal studies with 95 methods that minimise selection and measurement biases, further updates with the study types included in this living systematic review are unlikely to be able to provide a reliable summary 96 97 estimate of the proportion of asymptomatic infections caused by SARS-CoV-2.
- 98 REVIEW PROTOCOL: Open Science Framework (https://osf.io/9ewys/)

99

100 AUTHOR SUMMARY

101 Why was this study done?

- The proportion of people who will remain asymptomatic throughout the course of infection with
 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease
 2019 (covid-19), is debated.
- Studies that assess people at just one time point overestimate the proportion of true asymptomatic
 infection because those who go on to develop covid-19 symptoms will be wrongly classified as
 asymptomatic, but other types of study might underestimate the proportion if, for example, people
 with symptoms are more likely to be included in a study population.
- The number of published studies about SARS-CoV-2 is increasing continuously, types of studies
 are changing and, since 2021, vaccines have become available, and variants of concern have
 emerged.

112 What did the researchers do and find?

- We updated a living systematic review through 6 July 2021, using automated workflows that
 speed up the review processes, and allow the review to be updated when relevant new evidence
 becomes available.
- In 130 studies, we found an interquartile range of 14-50% (prediction interval 2-90%) of people
 with SARS-CoV-2 infection that was persistently asymptomatic; owing to heterogeneity, we did
 not estimate a summary proportion.
- Contacts of people with asymptomatic SARS-CoV-2 infection are less likely to become infected
 than contacts of people with symptomatic infection (risk ratio 0.38, 95% CI 0.16-0.64, prediction
 interval 0.11-0.95, 8 studies).
- 122 What do these findings mean?
- Up to mid-2021, most people with SARS-CoV-2 were not persistently asymptomatic and
 asymptomatic infection was less infectious than symptomatic infection.
- In the presence of high between-study variability, summary estimates from meta-analysis may be
 misleading and prediction intervals should be presented.
- Future studies about asymptomatic SARS-CoV-2 infections caused by variants of concern and in
 people with immunity following vaccination or previous infection should be specifically
 designed, using methods to minimise biases in the selection of study participants and in
 ascertainment, classification and follow-up of symptom status.

131

132 Introduction

133

There is ongoing debate about the true proportion of severe acute respiratory syndrome coronavirus 2 134 135 (SARS-CoV-2) infection that remains asymptomatic [1]. A well-recognised source of overestimation 136 arises when people without symptoms at the time of testing are reported as having asymptomatic infection, with such cross-sectional studies often reporting percentages of 80% or more [2,3]. These 137 studies overestimate the proportion of persistently asymptomatic infection because they misclassify 138 people with so-called presymptomatic infection, who will develop symptoms of coronavirus disease 139 140 2019 (COVID-19) if reassessed after an adequate follow-up period [1]. Other sources of bias can 141 result in over- or underestimation of the proportion with persistent asymptomatic infections, even when participants are adequately followed up [1]. For example, studies that assess a limited range of 142 symptoms could overestimate the proportion asymptomatic through misclassification if they do not 143 ask participants about all possible symptoms. Since COVID-19 was first identified as a viral 144 pneumonia, the spectrum of symptoms has grown to include gastro-intestinal symptoms and 145 146 disturbances of smell and taste [1]. On the other hand, selection bias would be expected to underestimate the proportion with asymptomatic SARS-CoV-2 if people with symptoms are more 147 148 likely to be tested for SARS-CoV-2 infection than those without symptoms [4]. Accurate estimates of the proportions of true asymptomatic and presymptomatic infections are needed 149 150 to determine the balance and range of control measures [5]. Recognition of asymptomatic and presymptomatic infections showed the importance of control measures such as physical distancing, 151 152 active case-finding through testing of asymptomatic people [6] and the need for rapid quarantine [7] 153 in the first waves. Since late 2020, vaccines have become available [8] and several SARS-CoV-2 variants of concern have spread internationally, with varying viral characteristics [9]. The number of 154 published studies about SARS-CoV-2 is also increasing continuously and the types of published 155 156 studies are also changing [10], including the designs of studies about asymptomatic infection. In systematic reviews of studies published to April 2021, reported point estimates from random effects 157

158 meta-analysis models range from 17 to 41% [11-16]. Authors of these reviews typically report values

of the I^2 statistic >90 [17,18], but heterogeneity is often not explored in detail and prediction

160	intervals, which give information about sampling error and variability between studies, are
161	recommended but rarely reported[17,19,20]. In this fifth update of our living systematic review [21]
162	we aimed to improve and understand the changing evidence over time for three review questions: (1)
163	Amongst people who become infected with SARS-CoV-2, what proportion does not experience
164	symptoms at all during their infection? (2) What is the infectiousness of people with asymptomatic
165	and presymptomatic, compared with symptomatic SARS-CoV-2 infection? (3) What proportion of
166	SARS-CoV-2 transmission is accounted for by people who are either asymptomatic throughout
167	infection, or presymptomatic?

168 Methods

- 169 We conducted an update of a living systematic review, a systematic review that provides an online
- 170 summary of findings and is updated when relevant new evidence becomes available [22]. The
- 171 protocol, which describes modifications for each update, was first published on 1 April 2020 and
- amended for this version on 18 June 2021, (https://osf.io/9ewys/). Previous versions have been posted
- as preprints [21,23] and published as a peer-reviewed article [12]. We report our findings according to
- 174 statements on preferred reporting items for systematic reviews and meta-analyses 2020 (S1 PRISMA
- 175 2020 Checklist) [24] and on synthesis without meta-analysis in systematic reviews (SWiM) [25].
- 176 Ethics committee review was not required for this review. Box 1 shows our definitions of symptoms,
- asymptomatic infection and presymptomatic status.

178 Box 1. Definitions of symptoms and symptom status in a person with SARS-CoV-2 infections

Symptoms: symptoms that a person experiences and reports. We used the authors' definitions. We searched included manuscripts for an explicit statement that the study participant did not report symptoms that they experienced. Some authors defined 'asymptomatic' as an absence of self-reported symptoms. We did not include clinical signs observed or elicited on examination.

Asymptomatic infection: a person with laboratory-confirmed SARS-CoV-2 infection, who has no symptoms, according to the authors' report, at the time of first clinical assessment and had no symptoms at the end of follow-up. The end of follow-up was defined as any of the following: virological cure, with one or more negative RT-PCR test results; follow-up for 14 days or more after the last possible exposure to an index case; follow-up for seven days or more after the first RT-PCR positive result.

Presymptomatic: a person with laboratory-confirmed SARS-CoV-2 infection, who has no symptoms, according to the authors' report, at the time of first clinical assessment, but who

developed symptoms by the end of follow-up. The end of follow-up was defined as any of the following: virological cure, with one or more negative RT-PCR test results; follow-up for 14 days or more after the last possible exposure to an index case; follow-up for seven days or more after the first RT-PCR positive result.

179 Information sources and search

- 180 We conducted the first search on 25 March 2020 and updated it on 20 April 2020, 10 June 2020, 2
- 181 February 2021 and, for this update, 6 July 2021. We searched the COVID-19 living evidence database
- 182 [26], which uses automated workflow processes to: (1) aggregate simultaneous daily searches of four
- 183 electronic databases (Medline, PubMed, Ovid Embase, bioRxiv and medRxiv), using medical subject
- headings and free-text keywords for SARS-CoV-2 infection and COVID-19; (2) de-duplicate the
- records; (3) tag records that are preprints; and (4) allow searches of titles and abstracts using Boolean
- 186 operators. We used the search function to identify studies of asymptomatic or presymptomatic SARS-
- 187 CoV-2 infection using a search string of medical subject headings and free text keywords (S1 Text).
- 188 We also examined articles suggested by experts and the reference lists of retrieved studies. Reports
- 189 were planned to be updated at 3-monthly intervals, with continuously updated searches.

190 Eligibility criteria

191 We included studies, in any language, of people with SARS-CoV-2 diagnosed by RT-PCR that

documented follow-up and symptom status at the beginning and end of follow-up or investigated the

193 contribution to SARS-CoV-2 transmission of asymptomatic or presymptomatic infection. We

194 included contact tracing and outbreak investigations, cohort studies, case-control studies, and

195 mathematical modelling studies. We amended eligibility criteria after the third version of the review

196 [12] in two ways. First, we excluded studies that only reported the proportion of presymptomatic

197 SARS-CoV-2 because the settings and methods of these studies were very different and their results

198 were too heterogeneous to summarise [12]. Second, we aimed to reduce the risk of bias from studies

- 199 with inclusion criteria based mainly on people with symptoms, which would systematically
- 200 underestimate the proportion of people with asymptomatic infection. We therefore excluded the
- following study types: case series restricted to people already diagnosed and studies that did not report
- the number of people tested for SARS-CoV-2, from whom the study population was derived. We also
- 203 excluded case reports and contact investigations of single individuals or families, and any study

- without sufficient follow-up (Box 1). Where data from the same study population were reported inmultiple records, we extracted data from the most comprehensive report.
- 206 Study selection and data extraction

Reviewers, including crowdsourced trained volunteers, worked in pairs to screen records using an 207 application programming interface in the electronic data capture system (REDCap, Vanderbilt 208 University, Nashville, TN, USA). One reviewer applied eligibility criteria to select studies and a 209 210 second reviewer verified all included and excluded studies. We reported the process in a flow diagram, adapted for living systematic reviews [27] (S1 Fig). The reviewers determined which of the 211 212 three review questions each study addressed. One reviewer extracted data using a pre-piloted 213 extraction form in REDCap and a second reviewer verified the extracted data. For both study 214 selection and data extraction, a third reviewer adjudicated on disagreements that could not be resolved 215 by discussion. We contacted study authors for clarifications. The extracted variables included, study 216 design, country and/or region, study setting, population, age, sex, primary outcomes and length of 217 follow-up (full list of variables in S1 Appendix). We extracted raw numbers of individuals with an 218 outcome of interest and relevant denominators from empirical studies. From statistical and 219 mathematical modelling studies we extracted proportions and 95% credibility intervals. 220 The primary outcomes for each review question were (1) the proportion of people with asymptomatic 221 SARS-CoV-2 infection who did not experience symptoms at all during follow-up; (2) secondary attack rate from asymptomatic or presymptomatic index cases, compared with symptomatic cases; (3) 222 model-estimated proportion of SARS-CoV-2 transmission accounted for by people who are 223 224 asymptomatic or presymptomatic.

225 Risk of bias in included studies

After the third version of the review [12], we developed a new tool to assess the risk of bias because the study designs of included studies have changed. In previous versions, we used items from tools to assess case series [28] and the prevalence of mental health disorders [29]. The new tool assessed possible biases in studies of prevalence in general and COVID-19 in particular [4,30]. We developed signalling questions in the domains of selection (two items), information (three items) and selective

231	reporting (one item) biases (S2 Text). For mathematical modelling studies, we used a checklist for
232	assessing relevance and credibility [31]. Two authors independently assessed the risk of bias, using a
233	customised online tool. A third reviewer resolved disagreements.
234 235	Synthesis of the evidence The data extracted and the code used to display and synthesise the results are publicly available:
236	https://github.com/leonieheron/LSR_Asymp_v4. We used the metaprop, metabin and metafor
237	functions from the meta package (version 4.11-0) [32] and the ggplot2 package (version 3.3.5) in R
238	(version 3.5.1). The 95% confidence intervals (CI) for each study were estimated using the Clopper-
239	Pearson method [33]. For review question 1, in contact or outbreak investigations, we subtracted the
240	index cases from the total with SARS-CoV-2 infection, because these people were likely to have been
241	identified because of their symptoms and their inclusion might lead to underestimation of the
242	asymptomatic proportion [16]. For all meta-analyses, we used stratified random effects models.
243	Where a meta-analysis was not done, we present the interquartile range (IQR) and describe
244	heterogeneity visually in forest plots, ordered by study sample size [25]. We calculated the I ² statistic,
245	which is the approximate proportion of between-study variability that is due to heterogeneity other
246	than chance and τ^2 , the between-study variance. We calculated 95% prediction intervals for all
247	summary estimates, to give a likely range of proportions that would have been obtained in
248	hypothetical studies conducted in similar settings [17,19,20]. We did subgroup analyses for pre-
249	specified characteristics of study design, setting and risk of bias and post-hoc analyses according to
250	age group and geographic region, comparing groups using a χ^2 test. We used meta-regression for post-
251	hoc analyses examining associations with study size and publication date. To compare our findings
252	with other studies, we extracted the raw data from five systematic reviews [11,13-16] and calculated
253	prediction intervals [17]. For review question 2, as a measure of infectiousness, we calculated the
254	secondary attack rate as the number of SARS-CoV-2-infected contacts as a proportion of all close
255	contacts ascertained. For each included study, we compared the secondary attack rate from
256	asymptomatic or presymptomatic index cases with that from symptomatic cases in the same study. If
257	there were no events in a group, we added 0.5 to each cell in the 2x2 table. We did not account for

10

258 potential clustering of contacts because the included studies did not report the number and size of 259 infection clusters consistently. We used the Hartung-Knapp method for random effects meta-analysis to estimate a summary risk ratio (with 95% CI) [34]. For review question 3, we reported the findings 260 261 descriptively because of large differences between study settings, methods and results. We did not 262 construct funnel plots to examine bias across studies because their utility in studies reporting on 263 proportions is not clear. 264 **Results** 265 The searches for studies about asymptomatic or presymptomatic SARS-CoV-2, on 25 March, 20 April and 10 June 2020 and 2 February and 6 July 2021 resulted in 89, 230, 688, 4,213 and 3,018 records 266 for screening, respectively (S1 Fig). Owing to changes in eligible study designs, this update excludes 267 67 articles from earlier versions (S1 Table). We included a total of 146 studies addressing one or more 268 269 review questions; 130 empirical studies that estimate the proportion of people with asymptomatic SARS-CoV-2 (summarised in Table 1 and S2 Table) [35-164], eight studies reporting on secondary 270 271 attack rates [35,81,131,142,165-168], and 13 mathematical modelling studies [7,165,169-179]. At the 272 time of the search on 6 July 2021, five records were preprints. We checked the publication status on 273 14 March 2022 and all were still preprints [61,62,88,169,171]. The review period from 1 January 274 2021 onwards includes 52 publications, three of which collected data during the period when the alpha variant of concern [85,125,133] had been described and vaccines were being introduced. 275 Proportion of people with asymptomatic SARS-CoV-2 infection 276

277 The 130 studies reported on 28,426 people with SARS-CoV-2 infection (11,923 defined as having

- asymptomatic infection) in 42 countries [35-164] (Table 1, S3Table). Amongst all 130 included
- studies, 88 studies used more than one method of follow-up to ascertain asymptomatic status (Table 1,
- 280 S2 Table). Only 22 of 130 studies reported the median or mean age [38,47,70,76,77,83,85,95,99,119-
- 281 121,124,126,128,133,134,139,143,146,152,164] and only five studies included children only
- 282 [65,67,110,115,118]. Only 31 studies reported the sex of people with asymptomatic SARS-CoV-2

283 (Table 1, S2 Table) [38,47,51,53,70,71,75,76,83,85,95,99,107,119-

284 122,124,126,128,133,134,139,143,146,147,150,153,158,162,164]. The types of included studies

- changed across the five versions of the review. In the first version [23], six of nine studies were
- 286 contact tracing investigations of single-family clusters. In this version, two main types of study design
- 287 generated the study populations of people with SARS-CoV-2: contact tracing or outbreak
- investigation methods were used to identify and test potentially infected contacts (46 studies, referred
- to as contact and outbreak investigations); and studies that involved screening of a defined group of
- 290 people in settings in the community, institutions, such as long-term care facilities, or occupational
- 291 groups (84 studies, referred to as screening studies).

292 Table 1. Summary of characteristics of studies reporting on proportion of asymptomatic SARS-

293 294

CoV-2 infections (review question 1)

	Study design and setting					
	Contact	Outbreak investigation	Screening of defined population			studies
	investigation		Community	Institutional	Occupational	
Total studies, n	13	33	23	43	18	130
Publication date						
Jan 2020 – Jun 2020	5	9	3	3	4	24
Jul 2020 – Dec 2020	5	17	11	17	6	56
Jan 2021 onward	3	7	9	23	8	50
Region ^b						
Africa	0	2	2	1	1	6
Americas	5	10	4	19	7	45
South-East Asia	0	3	2	2	1	7
Europe	2	13	7	18	5	45
Eastern Mediterranean	0	0	3	2	2	8
Western Pacific	6	6	5	1	2	19
Follow-up method ^c						
14 days after last possible	7	11	2	3	4	27
exposure						
≥7 days after diagnosis	11	27	19	35	16	108
Until negative RT-PCR result	2	4	9	12	6	33
Two or more follow-up methods	8	21	17	28	14	88
Age range of study participants						
Children (<18 years)	1	1	0	3	0	5
Adults (18 – 65 years)	3	10	9	16	14	52
Older adults (>65 years)	0	7	0	6	0	13
All ages	7	14	10	15	2	48
No information about age	2	1	4	3	2	12
Total with SARS-CoV-2 infection, n	1076	4910	10652	8921	2867	28426
Asymptomatic SARS-CoV-2 infections	264	1409	6007	3658	585	11923
Gender of asymptomatic cases ^c						
Male	1	33	1419	30	16	1499
Female	0	32	589	313	26	960

- 296 December
- ^aS2 Table reports the characteristics of each study included;
- ^bWorld Health Organization regions;
- ^c Studies could have more than one method of follow-up (S2 Table);
- 300 ^d 99 studies did not report the gender of asymptomatic cases.
- 301 Between-study heterogeneity was considerable, so we did not estimate a mean proportion of
- 302 asymptomatic infections overall, or for screening studies (Fig 1). The IQR of estimates for all 130
- included studies (141 clusters) was 14-50% (prediction interval 2-90%). In 46 studies enrolling people
- 304 found through contact or outbreak investigations, for example in long-term care facilities, in
- aeroplanes, or on cruise ships, we estimated a summary estimate for the proportion asymptomatic
- 306 (19%, 95% CI 15-25%, prediction interval 2-70%, IQR 8-37%). The estimated proportions of
- 307 asymptomatic SARS-CoV-2 infections were similar in studies of contact investigations (16%, 95% CI
- 308 9-27%, IQR 8-38%, 13 studies) and outbreak investigations (20%, 95% CI 15-28%, IQR 8-38%, 33
- studies) (S2 Fig).
- In 84 screening studies, the IQR for estimates from individual studies was 20-65% and the prediction
- 311 interval was 4-94% [41-48,50-54,56,58-63,67,69-71,73,74,79,83,86,88-97,99-101,103-
- 312 105,107,109,110,114-117,119,120,122,124-126,128,130,133-138,143-145,147,150-156,158-164].
- 313 The ranges of estimates were similar in three settings in which screening studies were conducted;
- people in a community setting (23 studies, IQR 20-53%, prediction interval 2-96%), institutional
- settings such as nursing homes (43 studies, IQR 26-67%, prediction interval 5-93%), and occupational
- settings such as amongst groups of healthcare workers (18 studies, IQR 17-64%, prediction interval 3-
- 317 95%) (S2 Fig).
- Three studies had data collection periods from 1 January 2021. In two nursing home outbreaks, 3/4 SARS-CoV-2 infections in partially vaccinated residents [133] and 13/14 infections (with the alpha variant) [85] in full vaccinated residents were asymptomatic. One study among healthcare workers did not report on symptom status according to vaccination or variant of concern but found that 76/155
- 322 (49%) with reinfection compared with 273/1704 (17%) with primary infection were asymptomatic
- 323 [125].

²⁹⁵ SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; Jan, January; Jun, June; Jul, July; Dec,

perpetuity. It is made available under a CC-BY 4.0 International license .

Study	Events	Total	Proportion	95% CI
Contact and outbreak investigations				
Pirnay JP	2	4	0.50	[0.07; 0.93]
Cardillo L [Healthcare workers]	2	4	0.50	[0.07; 0.93]
Garibaldi [Staff]	0	8	0.00	[0.00; 0.37]
Corcorran MA	3	8 *	0.38	[0.09; 0.76]
Yang N	2	10	0.20	[0.03; 0.56]
Hijnen D	1	11	0.09	[0.00; 0.41]
Schwierzeck V	2	11	0.18	[0.02; 0.52]
Danis K	1	12	0.08	[0.00; 0.38]
Garibaldi [Residents]	1	12	0.08	[0.00; 0.38]
Zhang W	4	12	0.33	[0.10; 0.65]
Romao VC	0	14	0.00	[0.00; 0.23]
Orsi A	13	14	0.93	[0.66; 1.00]
Böhmer MM	1	16	0.06	[0.00; 0.30]
Dora AV	6	16	0.38	[0.15; 0.65]
Yau K	7	20	0.35	[0.15; 0.59]
Cheng HY	4	22	0.18	[0.05; 0.40]
Redditt V	3	24	0.12	[0.03; 0.32]
Tian S	7	24	0.29	[0.13; 0.51]
Harada S [Patients]	8	24	0.33	[0.16; 0.55]
Park JH	4	28	0.14	[0.04; 0.33]
Patel MC	13	35	0.37	[0.21; 0.55]
Brandstetter S	2	36	0.06	[0.01; 0.19]
Kittang BR	0	40	0.00	[0.00; 0.09]
Pavli A	7	46	0.00	[0.06; 0.29]
Yousaf AR	ó	40	0.00	[0.00; 0.08]
Arons MM	3	47	0.06	[0.01; 0.18]
Wu J	5	47 48	0.00	[0.03; 0.23]
	25	40	0.51	
Harada S [Healthcare workers] Xie W	25 4	53	0.08	[0.36; 0.66]
	26	53	0.08	[0.02; 0.18] [0.35; 0.63]
Ladhani SN [Healthcare workers] van den Besselaar JH [Healthcare workers]	20	54	0.49	[0.00; 0.10]
Schmitt J	18	54	0.02	[0.21; 0.47]
Gettings JR	31	55	0.56	[0.42; 0.70]
	14	66	0.56	
Plucinski MM	29	71	0.21	[0.12; 0.33]
Njuguna H				[0.29; 0.53]
Jones A	24	87	0.28	[0.19; 0.38]
Cardillo L [Patients]	20		0.22	[0.14; 0.32]
Park SY	4	95 •	0.04	[0.01; 0.10]
Taylor J [Healthcare personnel]	9	99	0.09	[0.04; 0.17]
Grijalva CG	34	102	0.33	[0.24; 0.43]
Ladhani SN [Residents]	46	105	0.44	[0.34; 0.54]
Paleker M	41	112	0.37	[0.28; 0.46]
van den Besselaar JH [Residents]	7	113 🛨	0.06	[0.03; 0.12]
Graham N	46	126	0.37	[0.28; 0.46]
Taylor J [Residents]	7	127 •	0.06	[0.02; 0.11]
Luo L2	8	127 🛨	0.06	[0.03; 0.12]
Shi Q	60	183	0.33	[0.26; 0.40]
Pham QT	89	208	0.43	[0.36; 0.50]
Hurst JH	87	293	0.30	[0.25; 0.35]
Kennelly SP [Nursing home staff]	97	395 🛨	0.25	[0.20; 0.29]
Lee JY	80	694	0.12	[0.09; 0.14]
Kennelly SP [Nursing home residents]	193	710 🛨	0.27	[0.24; 0.31]
Kasper MR	572	1271	0.45	[0.42; 0.48]
Prediction interval				[0.02; 0.70]

Figure 1. Forest plot of proportion of people with 324 325 asymptomatic SARS-CoV-2 infection, stratified by 326 study design. In contact and outbreak investigations, the 327 summary estimate for meta-analysis was 19% (15-25%) 328 and the interquartile range (IQR) was 8-37%. In 329 screening studies, the IQR was 20-65%. Across all 330 studies, the IQR was 14-50%. The x-axis displays 331 proportions. The red bar shows the prediction interval 332 below each group of studies, with the prediction 333 interval for all studies at the bottom of the forest plot . 334 Where more than one cluster was reported, clusters are 335 annotated with [cluster identity].

Screening Hoehl S Tanacan A Jeffery-Smith A [Staff] Fisher MJ Chang L Berghoff AS Vohra [Undergoing chemotherapy] Pampiona J Rauch JN AbdulRahman A Vihuela MC Bender WR Lalani T van Buul LW [Healthcare workers] Ferreira VH Vohra [Presurgical patients] Theuring S [School students and staff] Varnall C Haidar G Morgan SC Kutsuna S Kirshblum SC Jeffery-Smith A [Residents] Theuring S [Household members] Hwang Isoldi S van Buul LW [Nursing home residents] Han X Wadhwa A Balestrini S Maki G Alshahrani MS Stock AD Bogani G Edelstein M Fakhim H Green R Martins Machado C Khondaker T Laws RL Pamplona J Rauch JN Laws RL Rivett L Starling A Rincon A Malagón-Rojas Pizarro-Sá ez MS Hogan CA Treibel TA Tan-Loh J Letizia AG Migisha R Patel MR Aslam A Marossy A London V Lavezzo E Chamie G Meyers KJ Smith E Weinbergero Wi YM va B Esteban I Nunes MC Turunen T Hcini N Wong J Lombardi A Shi SM Lombardi A Shi SM Andrikopoulou M Blain H Say D Beiting KJ Uçkay, I Eythorsson E Carlani L Al-Oahtani M Adhikari EH Hussain A Cao S Marcus JE Ghinai I Mahajan NN Uysal E Almazeedi S Hall V.I Malhotra S Abraha HE Ren R White EM Prediction interval

 $\begin{array}{c}10\\10\\11\\11\\12\\13\\14\\15\\16\\17\\17\\18\\19\\90\\12\\22\\26\\80\\15\\58\\84\\46\\15\\56\\68\\78\\1\end{array}$

1612 2194

0 0.2

Prediction interval

0.500 0.007 0.67 0.50 0.500 0.5[0.17; 0.49] [0.04; 0.28] [0.36; 0.69] [0.15; 0.43] [0.05; 0.26] [0.79; 0.97] [0.24; 0.51] [0.65; 0.88] [0.46; 0.71] 0.69 [0.56; 0.79] [0.28; 0.52] $\begin{array}{c} [0.66, 0.86]\\ [0.31, 0.51]\\ [0.23, 0.51]\\ [0.37, 0.75]\\ [0.07, 0.20]\\ [0.07, 0.20]\\ [0.07, 0.20]\\ [0.07, 0.18]\\ [0.07, 0.19]\\ [0.07, 0.18]\\ [0.07, 0.18]\\ [0.07, 0.19]\\ [0.22, 0.37]\\ [0.05, 0.14]\\ [0.22, 0.36]\\ [0.33, 0.48]\\ [0.33, 0.$ ----

0.8

0.4 0.6

[0.04: 0.94]

[0.02; 0.90]

336 Risk of bias in individual studies

337	There were risks of bias in all types of empirical studies (S3 Fig). In pre-specified subgroup analyses
338	according to risk of bias domains (S4 Table2), statistical heterogeneity remained very high ($I^2 \ge 84\%$)
339	and the prediction intervals remained wide. In screening studies, the summary proportion in was
340	lower in studies judged to be at low risk of information bias in the assessment of symptoms (29%,
341	95% CI 20-42%) than in studies at unclear or high risk of bias (47%, 95% CI 37-57%) (p=0.03, test
342	for subgroup differences). For all other domains, estimates of the proportion asymptomatic were not
343	associated with the assessment of the risk of bias.
344 345	Factors associated with proportion of asymptomatic SARS-CoV-2 Table 2 shows analyses for factors pre-specified in the protocol and post-hoc (Table 2). Study design
346	and setting was pre-specified and explained 16% of the variance in heterogeneity; estimates ranged
347	from 16% (8-29%) for contact investigations to 45% (35-56%) for screening studies in institutional
348	settings (S2 Fig). The date of publication was associated with the estimate of the proportion

349 asymptomatic (S4 Fig), increasing in more recent publications (p 0.03), although this only explained

4% of the variance in heterogeneity. There was some evidence of variability in different world regions

351 (p=0.06), explaining 9% of the heterogeneity. Sample size and age range of the study participants did

352 not appear to influence the estimated asymptomatic proportion. In three systematic reviews that we re-

analysed, prediction intervals were: 1-83% (241 studies [14]); 4-97% (95 studies [15]); and 3-89%

354 (170 studies [16]). I² values were between 94% and 99% (S2 Appendix).

355

356 Table 2. Summary of findings of subgroup and meta-regression analyses of factors associated with the proportion of asymptomatic SARS-CoV-2 infections 357

Variable	Clusters ^a	Proportion at the reference value (95% CI)	τ ^{2b}	p value (subgroup difference/ intercept)	Heterogeneity variance explained ^c
Reference	141	0.32 (0.27–0.38)	2.19	-	-
Study design and setting ^d					
Contact investigation	13	0.16 (0.08; 0.29)	1.87	< 0.001	16%
Outbreak investigation	40	0.20 (0.14; 0.28)			
Screening: community	24	0.39 (0.26; 0.53)			
Screening: institutional	46	0.45 (0.35; 0.56)			
Screening: occupational	18	0.41 (0.26; 0.59)			
Age group ^e					
All ages	57	0.28 (0.21-0.37)	2.11	0.38	4%
Adults (18-65 years)	52	0.36 (0.27-0.47)			
Older adults (>65 years) only	14	0.25 (0.13-0.44)			
Children (<18 years) only	5	0.27 (0.09-0.58)]		
Not reported	13	0.45 (0.27-0.66)			
Geographic region ^{e f}					
Americas	47	0.37 (0.27-0.47)	2.00	0.06	9%
Europe	52	0.24 (0.17-0.33)			
Western Pacific	20	0.35 (0.21-0.51)			
SE Asia	8	0.22 (0.09-0.43)			
East Mediterranean	8	0.59 (0.33-0.81)			
Africa	6	0.47 (0.22-0.74)			
Selection bias ^{a d}		· · · · · ·			
Low risk	54	0.34 (0.25-0.44)	2.19	0.67	0%
Unclear/high risk	87	0.31 (0.25-0.39)			
Information bias, assessment of s	ymptoms d	lefining status ^{a d}			
Low risk	33	0.25 (0.16-0.36)	2.15	0.14	2%
Unclear/high risk	108	0.35 (0.28-0.42)			
Information bias, misclassificatio	n based on	follow-up ^{a d}			
Low risk	107	0.32 (0.25-0.38)	2.19	0.65	0%
Unclear/ high risk	34	0.35 (0.24-0.47)			
Selective reporting bias ^{a d}					
Low risk	126	0.33 (0.27-0.40)	2.17	0.37	1%
Unclear/ high risk	15	0.25 (0.13-0.43)	1		1.0
Sample size ^g					
Proportion at sample size 50	-	0.29 (0.14-0.51)	1.91	0.06	13%
Proportion at sample size 120	_	0.31 (0.24-0.39)			
Proportion at sample size200	-	0.32 (0.24-0.40)	1		
Publication date	1			1	
Reference (first date, 19 Feb 2020)	-	0.21 (0.13-0.32)	2.09	< 0.001	4%
Coefficient	_	0.50 (0.50–0.50)			
CL confidence interval	1		1	1	<u> </u>

358 CI, confidence interval

359 ^a Total number of studies, 130; independent within-study clusters counted individually;

^b Common heterogeneity parameter estimated within each subgroup; 360

^c Formula for proportion of heterogeneity variance explained, $\frac{\tau_{unadjusted}^2 - \tau_{adjusted}^2}{\tau_{unadjusted}^2}$ 361

^d Pre-specified analysis in review protocol 362

^e Subgroup analysis not specified in review protocol 363

364 ^f World Health Organization regions;

^g Prevalence estimated using the meta-regression model for the approximate values of the median (n=46), the

366 mean (n=202) and the third quartile (n=126) of study sample sizes.

- 367
- 368 Infectiousness of people with asymptomatic or presymptomatic SARS-CoV-2
- 369 Eight studies provided data to calculate and to compare secondary attack rates by symptom status of
- the index case (Fig 2) [35,81,131,142,165-168]. Seven studies compared the secondary attack rate
- from asymptomatic with symptomatic index cases (summary risk ratio 0.32 (95% CI 0.16-0.64,
- prediction interval 0.11-0.95) [81,131,142,165-167]. One study compared asymptomatic with
- 373 presymptomatic index cases (summary risk ratio 0.19, 95% CI 0.02-1.46) [35] and four studies
- 374 compared presymptomatic with symptomatic index cases (summary risk ratio 1.00 (95% CI 0.37-
- 2.71, prediction interval 0.11-9.12) [81,142,166,167]. The risk of information bias, specifically in
- 376 symptom assessment, was judged to be high or unclear in five of the eight studies included (S3 Fig).

Study	E/N	E/N (Symp.) Risk Ratio	RR 95% CI			
Asymptomatic vs. Symptomatic							
Bender JK	0/26	9/82		0.16 [0.01; 2.72]			
Cheng HY	0/91	22/2644		0.64 [0.04; 10.51]			
Park SY	0/4	34/210		0.68 [0.05; 9.42]			
Luo L1	1/305	117/2305		0.06 [0.01; 0.46]			
Chaw L	3/106	28/1010		1.02 [0.32; 3.30]			
Gettings JR	6/200	51/467	<u>———</u>	0.27 [0.12; 0.63]			
Wu P	12/1078	128/3136		0.27 [0.15; 0.49]			
Random effects mo	odel		\diamond	0.32 [0.16; 0.64]			
Prediction interval				[0.11; 0.95]			
Heterogeneity: $I^2 = 20$	$1\%, \tau^2 = 0.1001$	1, <i>p</i> = 0.28					
Asymptomatic vs. I	Presymptom	atic					
Zhang W	1/119	11/250		0.19 [0.02; 1.46]			
Random effects mo	odel			0.19 [0.02; 1.46]			
Prediction interval							
Heterogeneity: not app	olicable						
Presymptomatic vs	. Symptoma	tic					
Park SY	0/11	34/210		0.27 [0.02; 4.06]			
Cheng HY	2/299	22/2644		0.80 [0.19; 3.40]			
Bender JK	15/72	9/82		1.90 [0.88; 4.07]			
Chaw L	12/585	28/1010		0.74 [0.38; 1.44]			
Random effects mo	odel		$ \rightarrow $	1.00 [0.37; 2.71]			
Prediction interval				[0.11; 9.12]			
Heterogeneity: $I^2 = 33$	%, τ ² = 0.1657	7, p = 0.22		-204 D - 0.000 - 0.000			
				L			
	2		0.01 0.1 1 10	100			
Test for subgroup diffe	erences: $\chi_2^2 = 8$	8.27, df = 2 (p	= 0.02)				

Figure 2. Forest plot of the secondary attack rate of SARS-CoV-2 infections comparing infections in contacts of asymptomatic and presymptomatic index cases with infections in contacts of symptomatic cases. The RR is on a logarithmic scale. The diamonds show the summary estimate and its 95% confidence interval. The red bar shows the prediction interval. CI, confidence interval; E, number of secondary transmission events; N, number of alone contacts pR rick ratio: Symptomatic individuals

382 of close contacts; RR, risk ratio; Symp. symptomatic individuals.

383

Contribution of asymptomatic and presymptomatic infection to SARS-CoV-2 transmission We included 13 mathematical modelling studies (Fig 3, S5 Table) [7,165,169-179]. The models in nine studies were informed by analyses of data from contact investigations in China, South Korea, Singapore, and from an outbreak on the *Diamond Princess* cruise ship, using data to estimate the serial interval or generation time [7,165,170,172,173,176-179]. In three studies the authors did not analyse any original data sources [169,174,175].

390 Estimates of the contributions of both asymptomatic and presymptomatic infections SARS-CoV-2

transmission were very heterogeneous. For asymptomatic SARS-CoV-2 infection, four studies

392 contributed five estimates [7,171,175,177]. In three studies, the estimates suggested a contribution to

393 SARS-CoV-2 transmission of asymptomatic infection of less than 15%. One study estimated a higher

proportion (69%, 95% CrI 20–85%) with a wide credibility interval [177] (Fig 3). The estimates have

395 large uncertainty intervals, and the disparate predictions result from differences in the proportion of

asymptomatic infections and relative infectiousness of asymptomatic infection.

397 We included 12 studies providing 16 estimates of the contribution of presymptomatic transmission

398 [7,165,169,170,172-179]. The models examined a range of epidemic settings and used different

399 assumptions about the durations and distributions of infection parameters such as incubation period,

400 generation time and serial interval (S5 Table). In seven studies, point estimates for the estimated

401 contribution of presymptomatic infection to all SARS-CoV-2 transmission in at least one reported

402 scenario were 40% or greater [7,169,170,172,173,175,176] (Fig 3). In one study that estimated a

403 contribution of <1% [174], the model-fitted serial interval was longer than observed in empirical

404 studies. The credibility of most modelling studies was limited by the absence of external validation

405 and of uncertainty intervals for the estimates cited. (S5 Fig). The estimates from studies that relied on

406 data from different published sources that might not have been compatible were assessed as providing

407 low quality evidence (S5 Table).

408

Study		Proportion	95% CI
Asymptomatic transmission			
Ferretti L	II	0.06	[0.00; 0.57]
Moghadas SM [17.9% asymptomatic]		0.03	
Moghadas SM [30.8% asymptomatic]		0.07	
Emery JC	L	0.69	[0.20; 0.85]
Tan J	-	0.13	[0.08; 0.19]
Pre-symptomatic transmission			
Ferretti L	H	0.47	[0.11; 0.58]
Zhang W [Early Transmission]		0.20	
Zhang W [Imported Cases]		0.80	
He X	H	0.44	[0.25; 0.69]
Peak CM [Short SI]	F	0.20	[0.00; 0.91]
Peak CM [Long SI]	x	0.00	[0.00; 0.01]
Tindale LC [Singapore]		0.74	
Tindale LC [Tianjin]		0.81	
Moghadas SM [17.9% asymptomatic]		0.48	
Moghadas SM [30.8% asymptomatic]	-	0.47	
Ren X		0.40	
Chun JY	H	0.37	[0.16; 0.52]
Wu P	⊢ ≡ →	0.38	[0.28; 0.49]
Bushman M	÷	0.34	[0.28; 0.41]
Sun K		0.53	
	· · · · · · · · · · · · · · · · · · ·		
	0 0.25 0.5 0.75 1		

409

410 Figure 3. Forest plot of proportion of SARS-CoV-2 infection resulting from asymptomatic or presymptomatic transmission. For studies that report outcomes in multiple settings or with alternative assumptions, these are 411

annotated in brackets. CI, confidence interval; SI, serial interval. 412

Discussion 413

414 Summary of main findings

415 1) For all 130 included studies, the IQR for the proportion of asymptomatic SARS-CoV-2 was 14-

416 50%, prediction interval 2-90%) and for 84 studies based on screening of defined populations, IQR

20-65% (prediction interval 4-94%). In 46 studies that identified participants through contact tracing 417

of index cases and outbreak investigations, the summary proportion from meta-analysis was 19% 418

419 (95% CI 15-25%, prediction interval 2-70%). 2) The risk ratio for the secondary attack rate from

asymptomatic compared with symptomatic infections was 0.38 (95% CI 0.16-0.64, prediction interval 420

421 0.11-0.95) and for presymptomatic infections compared with symptomatic infection was 1.00 (95%)

422 CI 0.37-2.71, prediction interval 0.11-9.12). 3) In mathematical modelling studies, estimated

423 proportions of all SARS-CoV-2 infections that result from transmission from asymptomatic

424 individuals were mostly below 15%, and from presymptomatic individuals mostly higher than 40%.

Evidence about asymptomatic infections caused by variants of concern, or with immunity following

426 infection or vaccination, is limited.

427 Strengths and weaknesses of the living systematic review methods A strength of the methodology of this review is the transparent reporting, with openly available data 428 and changes over different versions reported in the protocol. Our inclusion criteria attempted to 429 430 reduce risks of bias and we developed a new tool to address potential biases in the studies included in this review. In contact investigations, we subtracted index cases from the total number of people with 431 SARS-CoV-2 to avoid underestimation of the proportion asymptomatic [16]. We examined 432 heterogeneity in detail and, as a result of the wide prediction interval, we chose not to report an 433 overall summary estimate [18,25]. A limitation of the methods for this living systematic review is that 434 this update only includes published studies up to 6 July 2021. This covers the period when vaccines 435 436 started to be rolled out and the alpha variant of concern became dominant in high-income countries. Although we made extensive efforts to comply with the planned 3-monthly updates, with weekly 437 438 searches and a continuous process of screening, data extraction and risk of bias assessment, the pace 439 of publications about SARS-CoV-2 exceeds the capacity of our crowd of reviewers [10,26]. Our 440 decision to include preprints compensates for some of the delay because these articles appear sooner 441 than peer-reviewed publications. In reviews of observational epidemiological studies, search terms are broad so the number of studies that needs to be screened is high, but the yield of included studies is 442 443 low. The four databases that we searched are not comprehensive, but they cover the majority of 444 publications and we do not believe that we have missed studies that would change our conclusions. We have also not considered the possible impact of false negative RT-PCR results, which might be 445 446 more likely to occur in asymptomatic infections [180] and would underestimate the proportion of asymptomatic infections [181]. 447

448 Comparison with other reviews and interpretation

The type of studies that provide estimates of the proportion of asymptomatic SARS-CoV-2 infections
and heterogeneity between them has changed over the course of the pandemic. In our living
systematic review, the prediction interval has widened from 23-37% in studies published up to 25
March 2020 [23], to 3-67% up to June 2020 [12], 2-89% up to 2 February 2021 [21] and remains at 2-

453 90% up to 6 July. We found three systematic reviews, in which authors reported restriction to studies 454 with adequate follow-up (S2 Appendix) [11,13,16]. In two of the reviews, authors also applied criteria to reduce the risks of selection bias, with summary estimates of 18% (95% CI 9–26%, I^2 84%, 9 455 studies) [13] and 23% (95% CI 16–30%, I² 92%, 21 studies) [11]. In both reviews, with studies 456 457 published up to mid-2020, many included studies used designs that we defined as contact or outbreak 458 investigations (Fig 1, S2 Table, S2 Fig). Sah et al. reviewed studies published up to April 2021 and 459 their subgroup estimate from studies in long-term care facilities, which include many outbreak 460 investigations, was 17.8%, 95% CI 9.7-30.3%, 15 studies [16]. The summary estimates from all these 461 reviews are compatible with our estimate from 46 studies in similar settings (19%, 95% CI 15-25%, prediction interval 2-70%, I² 90%) (Fig 1). 462

It may not be possible to obtain a single summary estimate from published literature of the proportion 463 464 of persistently asymptomatic SARS-CoV-2 infection. Estimates from meta-analysis might be precise, 465 but are likely to be unreliable owing to unacceptably high levels of heterogeneity. In three large systematic reviews, overall estimates had narrow confidence intervals [14-16], but I² values were 94-466 467 99% and prediction intervals, which show the extent of all between-study variability were not 468 reported [17]. The prediction intervals that we calculated extended more or less from zero to 100% 469 (S2 Appendix), making differences in estimates between these studies hard to interpret. We expected 470 this update to our living systematic review to provide a more precise and less heterogeneous estimate 471 of the proportion of people with asymptomatic SARS-CoV-2 than in the previous version [12]. In 472 particular, we expected that studies that detect SARS-CoV-2 through screening of defined populations 473 and follow up of those infected would be less affected by biases in study methodology [30] and would 474 provide a more accurate estimate of persistently asymptomatic SARS-CoV-2, which should be 475 influenced mainly by properties of the virus and the host response to infection [182]. Study design 476 was the factor that explained the largest proportion of variability in this review (S2 Appendix). 477 Information bias, resulting from the way in which asymptomatic status is determined, was the factor 478 most strongly associated with the estimated proportion of asymptomatic infection in screening studies 479 (Table 2). Studies based on contact and outbreak investigations might obtain more detailed data about

symptoms, resulting in lower estimates of the proportion that is classified as asymptomatic. Symptom
report also differs between different groups of study participants, even within the same study, and
could also contribute to heterogeneity [183]. Age might play a role as children appear more likely
than adults to have an asymptomatic course of infection, but age was poorly reported and could not be
examined in detail (Table 1, Table 2).

485 The analysis of secondary attack rates in this update now provides strong evidence of lower

486 infectiousness of people with asymptomatic than symptomatic infection (Fig 2). The difference in

487 secondary attack rates between asymptomatic and symptomatic index cases in our meta-analysis is

488 smaller and less biased than in systematic reviews that analyse groups of studies reporting

489 asymptomatic index cases and of symptomatic cases separately [182,184]. In meta-analyses of two

490 proportions, the direct comparison within studies reduces heterogeneity and is less biased [34]. Since

491 SARS-CoV-2 can be transmitted a few days before the onset of symptoms [185], presymptomatic

492 transmission likely contributes substantially to overall SARS-CoV-2 epidemics. If both the proportion

and transmissibility of asymptomatic infection are relatively low, people with asymptomatic SARS-

494 CoV-2 infection should account for a smaller proportion of overall transmission than presymptomatic

495 individuals. This is consistent with the findings of modelling studies in our review, although the

absence of descriptions of the epidemic context in many studies made it difficult to compare findings

497 across studies.

498 Implications and unanswered questions

499 This living systematic review shows the challenges of synthesising evidence from observational

500 epidemiological studies. Heterogeneity in systematic reviews of prevalence is a recognised challenge

501 [34,186]. Methodological guidance to refrain from meta-analysis, and to report prediction intervals,

502 when the variability between studies is extreme is often ignored in favour of summary estimates,

which are easy to cite [18,20]. Part of the heterogeneity in our review arises from the fact that many

- studies were not designed to estimate the proportion of asymptomatic SARS-CoV-2 infection. The
- 505 incomplete descriptions of inclusion criteria, response rates, follow-up and of definitions of symptom

22

status [1] made it difficult to assess the risks of bias and to investigate their contribution to between-study heterogeneity.

508 The finding that, in studies of contact and outbreak investigations, a substantial minority of people 509 with SARS-CoV-2 infection remains asymptomatic throughout the course of infection, and that 510 almost half of all transmission might occur before symptoms develop has already had implications for prevention. When SARS-CoV-2 community transmission levels are high, physical distancing 511 measures and mask-wearing need to be sustained to prevent transmission from close contact with 512 people with asymptomatic and presymptomatic infection. Integration of evidence from 513 514 epidemiological, clinical and laboratory studies will help to clarify the relative infectiousness of asymptomatic SARS-CoV-2. Studies using viral culture as well as RNA detection are needed since 515 516 RT-PCR defined viral loads appear to be broadly similar in asymptomatic and symptomatic people 517 [180,187].

518 Determining the viral dynamics and full clinical spectrum of infection with variants of concern is 519 important. Variants classed as omicron differ substantially from all earlier SARS-CoV-2 variants. with high infectiousness and immune evasion [188], and viral characteristics and immunity could 520 influence the occurrence of asymptomatic infection. Studies published in early 2022 are already 521 reporting a wide range of estimates of asymptomatic omicron infection. In India, from the date of 522 523 emergence of the omicron variant, 24 November 2021 to 4 January 2022, authors reported a high 524 proportion of asymptomatic omicron variant infections (56.7% of 291) but did not report any followup and >80% of participants had been vaccinated [189]. In contrast, authors of a cohort study of an 525 outbreak of omicron SARS-CoV-2 in Norway, found only 1 of 81 infections in a highly vaccinated 526 527 group was asymptomatic after 10 days of follow-up [190]. There are increasing challenges for studies relying on routine health service or surveillance data; in many jurisdictions, indications for routine 528 529 testing are being reduced, which will make selection biases more likely, and mandated quarantine and 530 isolation periods for people with diagnosed SARS-CoV-2 infection are being reduced, which will 531 increase information biases in the ascertainment of persistent asymptomatic status. Researchers need 532 to design studies to address this specific research question for each variant of concern, taking into

23

- 533 account vaccination status and prior infection. There are ongoing prospective studies that collect
- appropriate data [125], for which improved reporting could address the requirements for assessing
- asymptomatic infection status fully, but ongoing funding for these studies is not secure [191]. Without
- 536 prospective longitudinal studies with methods that minimise selection and measurement biases,
- 537 further updates to this living systematic review are unlikely to provide a reliable summary estimate of
- the proportion of asymptomatic infections caused by SARS-CoV-2.

539 References

540

Meyerowitz EA, Richterman A, Bogoch I, Low N, Cevik M. Towards an Accurate and
 Systematic Characterisation of Persistently Asymptomatic Infection with Sars-Cov-2. Lancet Infect
 Dis 2021;21(6):e163-e9. Epub 2020/12/11. <u>https://doi.org/10.1016/S1473-3099(20)30837-9</u> PubMed
 PMID: 33301725; PubMed Central PMCID: 7834404.

- Day M. Covid-19: Four Fifths of Cases Are Asymptomatic, China Figures Indicate. BMJ.
 2020;369:m1375. Epub 2020/04/04. <u>https://doi.org/10.1136/bmj.m1375</u>. PubMed PMID: 32241884.
- 547 3. Ing AJ, Cocks C, Green JP. Covid-19: In the Footsteps of Ernest Shackleton. Thorax.
 548 2020;75(8):693-4. <u>https://doi.org/10.1136/thoraxjnl-2020-215091</u>.

549 4. Griffith GJ, Morris TT, Tudball MJ, Herbert A, Mancano G, Pike L, et al. Collider Bias
550 Undermines Our Understanding of Covid-19 Disease Risk and Severity. Nature Communications.
551 2020;11(1):5749. <u>https://doi.org/10.1038/s41467-020-19478-2</u>.

5. Lipsitch M, Swerdlow DL, Finelli L. Defining the Epidemiology of Covid-19 - Studies
Needed. N Engl J Med. 2020. Epub 2020/02/20. <u>https://doi.org/10.1056/nejmp2002125</u>. PubMed
PMID: 32074416.

Liu Y, Morgenstern C, Kelly J, Lowe R, Jit M. The Impact of Non-Pharmaceutical
Interventions on Sars-Cov-2 Transmission across 130 Countries and Territories. BMC Med.
2021;19(1):40. Epub 20210205. <u>https://doi.org/10.1186/s12916-020-01872-8</u>. PubMed PMID:
33541353; PubMed Central PMCID: 7861967.

Ferretti L, Wymant C, Kendall M, Zhao L, Nurtay A, Abeler-Dorner L, et al. Quantifying
Sars-Cov-2 Transmission Suggests Epidemic Control with Digital Contact Tracing. Science.
2020;368(6491). Epub 2020/04/03. <u>https://doi.org/10.1126/science.abb6936</u>. PubMed PMID:
32234805; PubMed Central PMCID: PMC7164555.

563 8. World Health Organization. Covid-19 Vaccines [Access Date:16.03.2020]. Available from:
 564 <u>https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines.</u>

9. World Health Organization. Tracking Sars-Cov-2 Variants [Access Date:16.03.2020].
Available from: <u>https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/</u>.

10. Ipekci AM, Buitrago-Garcia D, Meili KW, Krauer F, Prajapati N, Thapa S, et al. Outbreaks of
Publications About Emerging Infectious Diseases: The Case of Sars-Cov-2 and Zika Virus. BMC
Med Res Methodol. 2021;21(1):50. Epub 20210311. <u>https://doi.org/10.1186/s12874-021-01244-7</u>.
PubMed PMID: 33706715; PubMed Central PMCID: 7948668.

571 11. Beale S, Hayward A, Shallcross L, Aldridge R, Fragaszy E. A Rapid Review and Meta572 Analysis of the Asymptomatic Proportion of Pcr-Confirmed Sars-Cov-2 Infections in Community
573 Settings [Version 1; Peer Review: 1 Approved with Reservations]. Wellcome Open Research.
574 2020;5(266). https://doi.org/10.12688/wellcomeopenres.16387.1.

574 2020;5(266). <u>https://doi.org/10.12688/wellcomeopenres.16587.1</u>.

575 12. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et al.
576 Occurrence and Transmission Potential of Asymptomatic and Presymptomatic Sars-Cov-2 Infections:
577 A Living Systematic Review and Meta-Analysis. PLoS Med. 2020;17(9):e1003346.
578 https://doi.org/10.1371/journal.pmed.1003346.

579 13. Byambasuren O, Cardona M, Bell K, Clark J, McLaws ML, Glasziou P. Estimating the
580 Extent of Asymptomatic Covid-19 and Its Potential for Community Transmission: Systematic Review

perpetuity. It is made available under a CC-BY 4.0 International license .

581 and Meta-Analysis. Official Journal of the Association of Medical Microbiology and Infectious Disease Canada. 2020;Volume 5(Issue 4):pp. 223-34. https://doi.org/10.3138/jammi-2020-0030. 582

Chen X, Huang Z, Wang J, Zhao S, Wong MC-S, Chong KC, et al. Ratio of Asymptomatic 583 14. Covid-19 Cases among Ascertained Sars-Cov-2 Infections in Different Regions and Population 584 585 Groups in 2020: A Systematic Review and Meta-Analysis Including 130 123 Infections from 241 586 Studies. BMJ Open. 2021;11(12):e049752. http://dx.doi.org/10.1136/bmjopen-2021-049752.

587 Ma Q, Liu J, Liu Q, Kang L, Liu R, Jing W, et al. Global Percentage of Asymptomatic Sars-15. 588 Cov-2 Infections among the Tested Population and Individuals with Confirmed Covid-19 Diagnosis: A Systematic Review and Meta-Analysis. JAMA Network Open. 2021;4(12):e2137257-e. 589 590 https://doi.org/10.1001/jamanetworkopen.2021.37257.

Sah P, Fitzpatrick MC, Zimmer CF, Abdollahi E, Juden-Kelly L, Moghadas SM, et al. 591 16. 592 Asymptomatic Sars-Cov-2 Infection: A Systematic Review and Meta-Analysis. Proc Natl Acad Sci U S A. 2021;118(34). Epub 2021/08/12. https://doi.org/10.1073/pnas.2109229118. PubMed PMID: 593 34376550; PubMed Central PMCID: 8403749. 594

595 17. Riley RD, Higgins JP, Deeks JJ. Interpretation of Random Effects Meta-Analyses. BMJ. 2011;342:d549. https://doi.org/10.1136/bmj.d549. 596

McKenzie JE, Brennan SE. Synthesizing and Presenting Findings Using Other Methods. 597 18. 598 Cochrane Handbook for Systematic Reviews of Interventions2019. p. 321-47. 599 https://doi.org/10.1002/9781119536604.ch12.

Higgins JPT, Thompson SG, Spiegelhalter DJ. A Re-Evaluation of Random-Effects Meta-600 19. Analysis. J R Stat Soc Ser A Stat Soc. 2009;172(1):137-59. https://dx.doi.org/10.1111%2Fj.1467-601 602 985X.2008.00552.x. PubMed PMID: 19381330.

603 20. Deeks JJ, Higgins J, Altman D. Chapter 10: Analysing Data and Undertaking Meta-Analyses. 2022. Available from: https://training.cochrane.org/handbook/current/chapter-10#section-10-10-2. 604

605 21. Buitrago-Garcia D, Ipekci AM, Heron L, Imeri H, Araujo-Chaveron L, Arevalo-Rodriguez I, 606 et al. Occurrence and Transmission Potential of Asymptomatic and Presymptomatic Sars-Cov-2 607 Infections: A Living Systematic Review and Meta-Analysis. medRxiv [Preprint]. 608 2022:2022.01.20.22269581. https://doi.org/10.1101/2022.01.20.22269581.

609 Elliott JH, Turner T, Clavisi O, Thomas J, Higgins JP, Mavergames C, et al. Living 22. 610 Systematic Reviews: An Emerging Opportunity to Narrow the Evidence-Practice Gap. PLoS Med. 2014;11(2):e1001603. https://doi.org/10.1371/journal.pmed.1001603. PubMed PMID: 24558353; 611 PubMed Central PMCID: 3928029. 612

613 23. Buitrago-Garcia D, Egli-Gany D, Counotte M, Hossmann S, Imeri H, Salanti G, et al. The Role of Asymptomatic Sars-Cov-2 Infections: Rapid Living Systematic Review and Meta-Analysis. 614 615 Version 1. medRxiv [Preprint]. 2020. https://doi.org/10.1101/2020.04.25.20079103

24. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The 616 617 Prisma 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71. 618

25. Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et al. Synthesis 619 620 without Meta-Analysis (Swim) in Systematic Reviews: Reporting Guideline. BMJ. 2020;368:16890. 621 https://doi.org/10.1136/bmj.16890.

perpetuity. It is made available under a CC-BY 4.0 International license .

622 26. Counotte M, Imeri H, Ipekci M, Low N. Covid-19 Living Evidence Bern: Institute of Social and Preventive Medicine, University of Bern; 2020 [Access Date; cited 2020 09.05.2020]. Covid-19 623 624 living evidence landing page]. Available from: https://ispmbern.github.io/covid-19/living-review/.

Kahale L, Elkhoury R, El Mikati I, Pardo-Hernandez H, Khamis A, Sch nemann H, et al. 625 27. Tailored Prisma 2020 Flow Diagrams for Living Systematic Reviews: A Methodological Survey and 626 627 a Proposal [Version 2; Peer Review: 1 Approved, 1 Approved with Reservations]. F1000Research. 2021;10(192). https://doi.org/10.12688/f1000research.51723.2. 628

629 28. Joanna Briggs Institute. The Joanna Briggs Institute Critical Appraisal Tools for Use in Jbi Systematic Reviews–Checklist for Case Series Adelaide2017 [Access Date:10.06.2020]. Available 630 631 from: https://joannabriggs.org/ebp/critical appraisal tools.

29. Boyle MH. Guidelines for Evaluating Prevalence Studies. Evid Based Ment Health. 632 1998;1(2):37-40. http://ebmh.bmj.com/content/1/2/37.full.pdf. 633

634 30. Accorsi EK, Qiu X, Rumpler E, Kennedy-Shaffer L, Kahn R, Joshi K, et al. How to Detect 635 and Reduce Potential Sources of Biases in Studies of Sars-Cov-2 and Covid-19. Eur J Epidemiol. 636 2021:179-96. Epub 2021/02/27. https://doi.org/10.1007/s10654-021-00727-7. PubMed PMID: 33634345; PubMed Central PMCID: 7906244. 637

638 31. Jaime Caro J, Eddy DM, Kan H, Kaltz C, Patel B, Eldessouki R, et al. Questionnaire to 639 Assess Relevance and Credibility of Modeling Studies for Informing Health Care Decision Making: An Ispor-Amcp-Npc Good Practice Task Force Report. Value Health. 2014;17(2):174-82. 640 641 https://doi.org/10.1016/j.jval.2014.01.003. PubMed PMID: 24636375.

642 32. Balduzzi S, Rucker G, Schwarzer G. How to Perform a Meta-Analysis with R: A Practical 643 Tutorial. Evid Based Ment Health. 2019;22(4):153-60. Epub 2019/09/30. 644 https://doi.org/10.1136/ebmental-2019-300117. PubMed PMID: 31563865.

645 33. Newcombe RG. Two-Sided Confidence Intervals for the Single Proportion: Comparison of 646 Seven Methods. Stat Med. 1998;17(8):857-72. https://doi.org/10.1002/(sici)1097-0258(19980430)17:8%3C857::aid-sim777%3E3.0.co;2-e. 647

648 34. Schwarzer G, Rücker G. Meta-Analysis of Proportions. Methods Mol Biol. 2022;2345:159-72. https://doi.org/10.1007/978-1-0716-1566-9_10. PubMed PMID: 34550590. 649

35. Zhang W, Cheng W, Luo L, Ma Y, Xu C, Qin P, et al. Secondary Transmission of 650 Coronavirus Disease from Presymptomatic Persons, China. Emerg Infect Dis. 2020;26(8):1924-6. 651 Epub 2020/05/27. https://doi.org/10.3201/eid2608.201142. PubMed PMID: 32453686; PubMed 652 Central PMCID: 7392433. 653

654 36. Yousaf AR, Duca LM, Chu V, Reses HE, Fajans M, Rabold EM, et al. A Prospective Cohort 655 Study in Nonhospitalized Household Contacts with Severe Acute Respiratory Syndrome Coronavirus 656 2 Infection: Symptom Profiles and Symptom Change over Time. Clin Infect Dis. 2021;73(7):e1841-657 e9. Epub 2020/07/29. https://doi.org/10.1093/cid/ciaa1072. PubMed PMID: 32719874; PubMed 658 Central PMCID: 7454397.

659 37. Yau K, Muller MP, Lin M, Siddiqui N, Neskovic S, Shokar G, et al. Covid-19 Outbreak in an 660 Urban Hemodialysis Unit. Am J Kidney Dis. 2020;76(5):690-5 e1. Epub 2020/07/19. 661 https://doi.org/10.1053/j.ajkd.2020.07.001. PubMed PMID: 32681983; PubMed Central PMCID: 662 7362862.

perpetuity. It is made available under a CC-BY 4.0 International license .

663 38. Yang N, Shen Y, Shi C, Ma AHY, Zhang X, Jian X, et al. In-Flight Transmission Cluster of Covid-19: A Retrospective Case Series. Infect Dis (Lond). 2020;52(12):891-901. Epub 2020/08/01. 664 https://doi.org/10.1080/23744235.2020.1800814. PubMed PMID: 32735163. 665

39. Xie W, Chen Z, Wang Q, Song M, Cao Y, Wang L, et al. Infection and Disease Spectrum in 666 Individuals with Household Exposure to Sars-Cov-2: A Family Cluster Cohort Study. J Med Virol. 667 2021;93(5):3033-46. Epub 20210212. https://doi.org/10.1002/jmv.26847. PubMed PMID: 33538342; 668 PubMed Central PMCID: PMC8014049. 669

- 670 40. Wu J, Huang Y, Tu C, Bi C, Chen Z, Luo L, et al. Household Transmission of Sars-Cov-2, Zhuhai, China, 2020. Clin Infect Dis. 2020;71(16):2099-108. Epub 2020/05/12. 671
- 672 https://doi.org/10.1093/cid/ciaa557. PubMed PMID: 32392331; PubMed Central PMCID: 7239243.

Wong J, Abdul Aziz ABZ, Chaw L, Mahamud A, Griffith MM, Ying-Ru LO, et al. High 673 41. 674 Proportion of Asymptomatic and Presymptomatic Covid-19 Infections in Travelers and Returning Residents to Brunei. J Travel Med. 2020. https://doi.org/10.1093/jtm/taaa066. 675

42. Wi YM, Lim SJ, Kim SH, Lim S, Lee SJ, Ryu BH, et al. Response System for and 676 677 Epidemiological Features of Covid-19 in Gyeongsangnam-Do Province in South Korea. Clin Infect Dis. 2021;72(4):661-7. Epub 2020/07/17. https://doi.org/10.1093/cid/ciaa967. PubMed PMID: 678 32672789; PubMed Central PMCID: 7454481. 679

680 43. White EM, Santostefano CM, Feifer RA, Kosar CM, Blackman C, Gravenstein S, et al. Asymptomatic and Presymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection 681 682 Rates in a Multistate Sample of Skilled Nursing Facilities. JAMA Intern Med. 2020;180(12):1709-11. 683 Epub 2020/10/20. https://doi.org/10.1001/jamainternmed.2020.5664. PubMed PMID: 33074318; 684 PubMed Central PMCID: 7573793.

685 44. Weinbergerova B, Mayer J, Hrabovsky S, Novakova Z, Pospisil Z, Martykanova L, et al. 686 Covid-19's Natural Course among Ambulatory Monitored Outpatients. Sci Rep. 2021;11(1):10124. 687 Epub 20210512. https://doi.org/10.1038/s41598-021-89545-1. PubMed PMID: 33980931; PubMed 688 Central PMCID: PMC8115337.

689 45. Wadhwa A, Fisher KA, Silver R, Koh M, Arons MM, Miller DA, et al. Identification of 690 Presymptomatic and Asymptomatic Cases Using Cohort-Based Testing Approaches at a Large 691 Correctional Facility-Chicago, Illinois, USA, May 2020. Clin Infect Dis. 2021;72(5):e128-e35. Epub 2020/12/04. https://doi.org/10.1093/cid/ciaa1802. PubMed PMID: 33270101; PubMed Central 692 693 PMCID: 7799274.

Vohra LM, Jabeen D, Asif N, Ahad A. Covid-19 Pandemic and Breast Cancer Management: 694 46. 695 A Retrospective Observational Clinical Study from Pakistan. Ann Med Surg (Lond). 2021;63:102151. 696 Epub 20210204. https://doi.org/10.1016/j.amsu.2021.01.099. PubMed PMID: 33564461; PubMed 697 Central PMCID: PMC7860941.

- Vinuela MC, De Leon-Luis JA, Alonso R, Catalan P, Lizarraga S, Munoz P, et al. Sars-Cov-2 698 47. 699 Screening of Asymptomatic Women Admitted for Delivery Must Be Performed with a Combination 700 of Microbiological Techniques: An Observational Study. Rev Esp Quimioter. 2020;33(6):415-21. 701 Epub 2020/09/19. https://doi.org/10.37201/req/088.2020. PubMed PMID: 32945157; PubMed 702 Central PMCID: 7712338.
- 703 48. Varnell C, Jr., Harshman LA, Smith L, Liu C, Chen S, Al-Akash S, et al. Covid-19 in 704 Pediatric Kidney Transplantation: The Improving Renal Outcomes Collaborative. Am J Transplant. 705 2021;21(8):2740-8. Epub 2021/01/17. https://doi.org/10.1111/ajt.16501. PubMed PMID: 33452854;
- PubMed Central PMCID: 8013281. 706

perpetuity. It is made available under a CC-BY 4.0 International license .

- 707 49. van den Besselaar JH, Sikkema RS, Koene F, van Buul LW, Oude Munnink BB, Frenay I, et
- al. Are Presymptomatic Sars-Cov-2 Infections in Nursing Home Residents Unrecognised 708
- 709 Symptomatic Infections? Sequence and Metadata from Weekly Testing in an Extensive Nursing
- 710 Home Outbreak. Age Ageing. 2021;50(5):1454-63. Epub 2021/05/09.
- https://doi.org/10.1093/ageing/afab081. PubMed PMID: 33963830; PubMed Central PMCID: 711
- 712 8136016.
- 713 50. van Buul LW, van den Besselaar JH, Koene F, Buurman BM, Hertogh C, Group** C-N-S, et
- 714 al. Asymptomatic Cases and Limited Transmission of Sars-Cov-2 in Residents and Healthcare
- Workers in Three Dutch Nursing Homes. Gerontol Geriatr Med. 2020;6:2333721420982800. Epub 715
- 2021/01/12. https://doi.org/10.1177/2333721420982800. PubMed PMID: 33426178; PubMed 716
- 717 Central PMCID: 7756037.
- Uysal E, Kilincer A, Cebeci H, Özer H, Demir NA, Öztürk M, et al. Chest Ct Findings in Rt-718 51. Pcr Positive Asymptomatic Covid-19 Patients. Clinical Imaging. 2021;77:37-42. 719 720 https://doi.org/10.1016/j.clinimag.2021.01.030.
- Uçkay I, Steinwender L, Burkhard J, Holy D, Strähl M, Farshad M. Outcomes of 721 52.
- Asymptomatic Hospital Employees in Covid-19 Post-Exposure Quarantine During the Second 722
- 723 Pandemic Wave in Zurich. J Hosp Infect. 2021;113:189-91. Epub 20210421.
- 724 https://doi.org/10.1016/j.jhin.2021.04.010. PubMed PMID: 33891983; PubMed Central PMCID: 725 PMC8057933.
- Turunen T, Kontunen K, Sugulle K, Hieta P, Snellman O, Hussein I, et al. Covid-19 Outbreak 726 53. 727 at a Reception Centre for Asylum Seekers in Espoo, Finland. J Migr Health. 2021;3:100043. Epub 728 20210416. https://doi.org/10.1016/j.jmh.2021.100043. PubMed PMID: 33880457; PubMed Central 729 PMCID: PMC8051004.
- 730 54. Treibel TA, Manisty C, Burton M, McKnight NA, Lambourne J, Augusto JB, et al. Covid-19: 731 Pcr Screening of Asymptomatic Health-Care Workers at London Hospital. Lancet. 2020. https://doi.org/10.1016/s0140-6736(20)31100-4. 732
- 733 55. Tian S, Wu M, Chang Z, Wang Y, Zhou G, Zhang W, et al. Epidemiological Investigation 734 and Intergenerational Clinical Characteristics of 24 Coronavirus Disease Patients Associated with a 735 Supermarket Cluster: A Retrospective Study. BMC Public Health. 2021;21(1):647. Epub 2021/04/03. 736 https://doi.org/10.1186/s12889-021-10713-z. PubMed PMID: 33794836; PubMed Central PMCID: 737 8016429.
- 738 56. Theuring S, Thielecke M, van Loon W, Hommes F, Hulso C, von der Haar A, et al. Sars-Cov-739 2 Infection and Transmission in School Settings During the Second Covid-19 Wave: A Cross-740 Sectional Study, Berlin, Germany, November 2020. Euro Surveill. 2021;26(34). Epub 2021/08/28. 741 https://doi.org/10.2807/1560-7917.es.2021.26.34.2100184. PubMed PMID: 34448448; PubMed 742 Central PMCID: 8393892.
- Taylor J, Carter RJ, Lehnertz N, Kazazian L, Sullivan M, Wang X, et al. Serial Testing for 743 57. 744 Sars-Cov-2 and Virus Whole Genome Sequencing Inform Infection Risk at Two Skilled Nursing Facilities with Covid-19 Outbreaks - Minnesota, April-June 2020. MMWR Morb Mortal Wkly Rep. 745 2020;69(37):1288-95. Epub 2020/09/24. https://doi.org/10.15585/mmwr.mm6937a3. PubMed PMID: 746 32966272; PubMed Central PMCID: 7498172. 747
- 748 58. Tanacan A, Erol SA, Turgay B, Anuk AT, Secen EI, Yegin GF, et al. The Rate of Sars-Cov-2 749 Positivity in Asymptomatic Pregnant Women Admitted to Hospital for Delivery: Experience of a 750 Pandemic Center in Turkey. Eur J Obstet Gynecol Reprod Biol. 2020;253:31-4. Epub 2020/08/09. https://doi.org/10.1016/j.ejogrb.2020.07.051. PubMed PMID: 32763728; PubMed Central PMCID: 751 7390745. 752

perpetuity. It is made available under a CC-BY 4.0 International license .

753 59. Tan-Loh J, Cheong BMK. A Descriptive Analysis of Clinical Characteristics of Covid-19 among Healthcare Workers in a District Specialist Hospital. Med J Malaysia. 2021;76(1):24-8. Epub 754 755 2021/01/30. https://pubmed.ncbi.nlm.nih.gov/33510104/. PubMed PMID: 33510104.

Stock AD, Bader ER, Cezavirli P, Inocencio J, Chalmers SA, Yassari R, et al. Covid-19 756 60. Infection among Healthcare Workers: Serological Findings Supporting Routine Testing. Front Med 757 758 (Lausanne). 2020;7:471. Epub 2020/09/26. https://doi.org/10.3389/fmed.2020.00471. PubMed PMID: 32974370; PubMed Central PMCID: 7472984. 759

- 760 61. Starling A, White E, Showell D, Wyllie D, Kapadia S, Balakrishnan R. Whole Care Home 761 Testing for Covid-19 in a Local Authority Area in the United Kingdom. medRxiv [Preprint]. 2020. 762 https://doi.org/10.1101/2020.08.06.20162859.
- 763 62. Smith E, Aldus CF, Brainard J, Dunham S, Hunter PR, Steel N, et al. Testing for Sars-Cov-2 764 in Care Home Staff and Residents in English Care Homes: A Service Evaluation. medRxiv [Preprint]. 2020. https://doi.org/10.1101/2020.08.04.20165928. 765
- Shi SM, Bakaev I, Chen H, Travison TG, Berry SD. Risk Factors, Presentation, and Course of 766 63. 767 Coronavirus Disease 2019 in a Large, Academic Long-Term Care Facility. J Am Med Dir Assoc. 2020;21(10):1378-83.e1. Epub 20200825. https://doi.org/10.1016/j.jamda.2020.08.027. PubMed 768 PMID: 32981664; PubMed Central PMCID: 7447263. 769
- 770 64. Shi Q, Hu Y, Peng B, Tang XJ, Wang W, Su K, et al. Effective Control of Sars-Cov-2 Transmission in Wanzhou, China. Nat Med. 2021;27(1):86-93. Epub 20201130. 771 772 https://doi.org/10.1038/s41591-020-01178-5. PubMed PMID: 33257893.
- Schwierzeck V, Konig JC, Kuhn J, Mellmann A, Correa-Martinez CL, Omran H, et al. First 773 65. 774 Reported Nosocomial Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 in a Pediatric Dialysis Unit. Clin Infect Dis. 2021;72(2):265-70. Epub 2021/01/28. 775
- https://doi.org/10.1093/cid/ciaa491. PubMed PMID: 33501962; PubMed Central PMCID: 7197625. 776
- 777 Schmitt J, Genet E, Danguy Des Deserts M, Chauvet-Atin S, Cungi PJ, Aries P, et al. Sars 66. 778 Cov2 Outbreak Management on a Landing Helicopter Dock: An Observational Retrospective Study.
- 779 Infect Dis Now. 2021;51(5):424-8. Epub 20210619. https://doi.org/10.1016/j.idnow.2021.06.303. 780 PubMed PMID: 34157429; PubMed Central PMCID: PMC8214318.
- 781 Say D, Crawford N, McNab S, Wurzel D, Steer A, Tosif S. Post-Acute Covid-19 Outcomes in 67.
- Children with Mild and Asymptomatic Disease. Lancet Child Adolesc Health. 2021;5(6):e22-e3. 782 783 Epub 20210421. https://doi.org/10.1016/s2352-4642(21)00124-3. PubMed PMID: 33891880; PubMed Central PMCID: PMC8057863. 784
- 785 Romao VC, Oliveira-Ramos F, Cruz-Machado AR, Martins P, Barreira S, Silva-Dinis J, et al. 68. 786 A Covid-19 Outbreak in a Rheumatology Department Upon the Early Days of the Pandemic. Front 787 Med (Lausanne). 2020;7:576162. Epub 2020/10/27. https://doi.org/10.3389/fmed.2020.576162. PubMed PMID: 33102507; PubMed Central PMCID: 7546334. 788
- 789 69. Rivett L, Sridhar S, Sparkes D, Routledge M, Jones NK, Forrest S, et al. Screening of 790 Healthcare Workers for Sars-Cov-2 Highlights the Role of Asymptomatic Carriage in Covid-19 791 Transmission. Elife. 2020;9. Epub 2020/05/12. https://doi.org/10.7554/elife.58728. PubMed PMID: 792 32392129.
- 793 70. Rincón A, Moreso F, López-Herradón A, Fernández-Robres MA, Cidraque I, Nin J, et al. The
- 794 Keys to Control a Covid-19 Outbreak in a Haemodialysis Unit. Clinical Kidney Journal.
- 795 2020;13(4):542-9. https://doi.org/10.1093/ckj/sfaa119.

perpetuity. It is made available under a CC-BY 4.0 International license .

- 796 71. Ren R, Zhang Y, Li Q, McGoogan JM, Feng Z, Gao GF, et al. Asymptomatic Sars-Cov-2 Infections among Persons Entering China from April 16 to October 12, 2020. Jama. 2021;325(5):489-797 92. https://doi.org/10.1001/jama.2020.23942. PubMed PMID: 33528529; PubMed Central PMCID: 798 799 PMC7856538.
- 800 Redditt V, Wright V, Rashid M, Male R, Bogoch I. Outbreak of Sars-Cov-2 Infection at a 72. 801 Large Refugee Shelter in Toronto, April 2020: A Clinical and Epidemiologic Descriptive Analysis. CMAJ Open. 2020;8(4):E819-E24. Epub 2020/12/10. https://doi.org/10.9778/cmajo.20200165. 802 803 PubMed PMID: 33293331; PubMed Central PMCID: 7743908.
- 804 73.
- Rauch JN, Valois E, Ponce-Rojas JC, Aralis Z, Lach RS, Zappa F, et al. Comparison of 805 Severe Acute Respiratory Syndrome Coronavirus 2 Screening Using Reverse Transcriptase-
- 806 Quantitative Polymerase Chain Reaction or Crispr-Based Assays in Asymptomatic College Students. 807 JAMA Netw Open. 2021;4(2):e2037129. Epub 2021/02/12.
- https://doi.org/10.1001/jamanetworkopen.2020.37129. PubMed PMID: 33570576; PubMed Central 808 809 PMCID: 7879237.
- 74. Plucinski MM, Wallace M, Uehara A, Kurbatova EV, Tobolowsky FA, Schneider ZD, et al. 810
- Coronavirus Disease 2019 (Covid-19) in Americans Aboard the Diamond Princess Cruise Ship. Clin 811 812 Infect Dis. 2021;72(10):e448-e57. Epub 2020/08/14. https://doi.org/10.1093/cid/ciaa1180. PubMed
- 813 PMID: 32785683; PubMed Central PMCID: 7454359.

814 75. Pizarro-Sanchez MS, Avello A, Mas-Fontao S, Stock da Cunha T, Goma-Garces E, Pereira 815 M, et al. Clinical Features of Asymptomatic Sars-Cov-2 Infection in Hemodialysis Patients. Kidney Blood Press Res. 2021;46(1):126-34. Epub 2021/01/28. https://doi.org/10.1159/000512535. PubMed 816 817 PMID: 33503627; PubMed Central PMCID: 7900451.

- Pirnay JP, Selhorst P, Cochez C, Petrillo M, Claes V, Van der Beken Y, et al. Study of a Sars-818 76. 819 Cov-2 Outbreak in a Belgian Military Education and Training Center in Maradi, Niger. Viruses. 820 2020;12(9). Epub 2020/09/02. https://doi.org/10.3390/v12090949. PubMed PMID: 32867108; 821 PubMed Central PMCID: 7552053.
- Thai PQ, Rabaa MA, Luong DH, Tan DQ, Quang TD, Quach HL, et al. The First 100 Days of 822 77. 823 Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) Control in Vietnam. Clin Infect Dis. 824 2021;72(9):e334-e42. Epub 2020/08/02. https://doi.org/10.1093/cid/ciaa1130. PubMed PMID: 825 32738143; PubMed Central PMCID: 7454342.
- 826 Pavli A, Smeti P, Papadima K, Andreopoulou A, Hadjianastasiou S, Triantafillou E, et al. A 78. 827 Cluster of Covid-19 in Pilgrims to Israel. J Travel Med. 2020;27(5). Epub 2020/06/26. https://doi.org/10.1093/jtm/taaa102. PubMed PMID: 32584403; PubMed Central PMCID: 7337872. 828
- 829 79. Patel MR, Kushwaha RS, Behera M, Bhadauria DS, Yachha M, Kaul A, et al. Aftermath of 830 Fortnightly Universal Testing for Severe Acute Respiratory Corona Virus-2 Infection in Maintenance 831 Hemodialysis Patients. Semin Dial. 2021;34(5):338-46. Epub 20210624.
- 832 https://doi.org/10.1111/sdi.12997. PubMed PMID: 34169574: PubMed Central PMCID:
- 833 PMC8447208.
- 834 80. Patel MC, Chaisson LH, Borgetti S, Burdsall D, Chugh RK, Hoff CR, et al. Asymptomatic
- 835 Sars-Cov-2 Infection and Covid-19 Mortality During an Outbreak Investigation in a Skilled Nursing 836 Facility. Clin Infect Dis. 2020;71(11):2920-6. Epub 2020/06/18. https://doi.org/10.1093/cid/ciaa763. 837 PubMed PMID: 32548628; PubMed Central PMCID: 7337684.
- 838 81. Park SY, Kim YM, Yi S, Lee S, Na BJ, Kim CB, et al. Coronavirus Disease Outbreak in Call 839 Center, South Korea. Emerg Infect Dis. 2020;26(8):1666-70. Epub 2020/04/24.

https://doi.org/10.3201/eid2608.201274. PubMed PMID: 32324530; PubMed Central PMCID: 7392450.

842 82. Park JH, Jang JH, Lee K, Yoo SJ, Shin H. Covid-19 Outbreak and Presymptomatic

843 Transmission in Pilgrim Travelers Who Returned to Korea from Israel. J Korean Med Sci.

844 2020;35(48):e424. Epub 2020/12/15. <u>https://doi.org/10.3346/jkms.2020.35.e424</u>. PubMed PMID: 33316860: PubMed Central PMCID: 7735917

845 33316860; PubMed Central PMCID: 7735917.

846 83. Pamplona J, Solano R, Ramírez M, Durandez R, Mohamed F, Pardo L, et al. High Prevalence
847 of Sars-Cov-2 Infection in Patients Scheduled for Digestive Endoscopy after the Peak of the First
848 Wave of the Pandemic. Gastroenterol Hepatol. 2021;44(9):614-9. Epub 20210420.
849 <u>https://doi.org/10.1016/j.gastrohep.2021.03.001</u>. PubMed PMID: 33862154; PubMed Central
850 PMCID: PMC8056966.

84. Paleker M, Tembo YA, Davies MA, Mahomed H, Pienaar D, Madhi SA, et al. Asymptomatic
Covid-19 in South Africa - Implications for the Control of Transmission. Public Health Action.
2021;11(2):58-60. <u>https://doi.org/10.5588/pha.20.0069</u>. PubMed PMID: 34159063; PubMed Central
PMCID: PMC8202632.

855 85. Orsi A, Domnich A, Pace VD, Ricucci V, Caligiuri P, Bottiglieri L, et al. Outbreak of Sars-856 Cov-2 Lineage 20i/501y.V1 in a Nursing Home Underlines the Crucial Role of Vaccination in Both

- 856 Cov-2 Lineage 20i/501y.V1 in a Nursing Home Underlines the C
 857 Residents and Staff. Vaccines. 2021;9(6):591. PubMed PMID:
- 858 https://doi.org/10.3390/vaccines9060591.

86. Nunes MC, Baillie VL, Kwatra G, Bhikha S, Verwey C, Menezes C, et al. Severe Acute
860 Respiratory Syndrome Coronavirus 2 Infection among Healthcare Workers in South Africa: A
861 Lancitudinal Cabert Study. Clin. Infect Dis. 2021;72(10):1806-000

Longitudinal Cohort Study. Clin Infect Dis. 2021;73(10):1896-900.

https://doi.org/10.1093/cid/ciab398. PubMed PMID: 33949670; PubMed Central PMCID: PMC8135922.

864 87. Njuguna H, Wallace M, Simonson S, Tobolowsky FA, James AE, Bordelon K, et al. Serial
865 Laboratory Testing for Sars-Cov-2 Infection among Incarcerated and Detained Persons in a

Correctional and Detention Facility - Louisiana, April-May 2020. MMWR Morb Mortal Wkly Rep.
 2020;69(26):836-40. Epub 2020/07/03. <u>https://doi.org/10.15585/mmwr.mm6926e2</u>. PubMed PMID:

868 32614816; PubMed Central PMCID: 7332096.

869 88. Morgan SC, Aigner S, Anderson C, Belda-Ferre P, De Hoff P, Marotz CA, et al. Automated,
870 Miniaturized, and Scalable Screening of Healthcare Workers, First Responders, and Students for Sars871 Cov-2 in San Diego County. medRxiv [Preprint]. 2021:2021.06.25.21257885.

872 <u>https://doi.org/10.1101/2021.06.25.21257885</u>.

873 89. Migisha R, Kwesiga B, Mirembe BB, Amanya G, Kabwama SN, Kadobera D, et al. Early
874 Cases of Sars-Cov-2 Infection in Uganda: Epidemiology and Lessons Learned from Risk-Based
875 Testing Approaches - March-April 2020. Global Health. 2020;16(1):114. Epub 2020/11/27.
876 https://doi.org/10.1186/s12992-020-00643-7. PubMed PMID: 33239041; PubMed Central PMCID:
877 7686950.

Meyers KJ, Dillman B, Williams C, Jiang J, Clifford N, Miller JL, et al. Follow-up of SarsCov-2 Positive Subgroup from the Asymptomatic Novel Coronavirus Infection Study. J Med Virol.
2021;93(5):2925-31. Epub 2021/01/20. <u>https://doi.org/10.1002/jmv.26810</u>. PubMed PMID:
33463731; PubMed Central PMCID: 8014630.

882 91. Marossy A, Rakowicz S, Bhan A, Noon S, Rees A, Virk M, et al. A Study of Universal
883 Severe Acute Respiratory Syndrome Coronavirus 2 Rna Testing among Residents and Staff in a Large

884 Group of Care Homes in South London. J Infect Dis. 2021;223(3):381-8. Epub 2020/09/06. 10.1093/infdis/jiaa565. PubMed PMID: 32889532; PubMed Central PMCID: PMC7499645. 885

Marcus JE, Frankel DN, Pawlak MT, Casey TM, Cybulski RJ, Jr., Enriquez E, et al. Risk 886 92. 887 Factors Associated with Covid-19 Transmission among Us Air Force Trainees in a Congregant Setting. JAMA Netw Open. 2021;4(2):e210202. Epub 20210201. 888

- 889 https://doi.org/10.1001/jamanetworkopen.2021.0202. PubMed PMID: 33630090; PubMed Central 890 PMCID: PMC7907953.
- 891 93. Malhotra S, Rahi M, Das P, Chaturvedi R, Chhibber-Goel J, Anvikar A, et al.
- 892 Epidemiological Profiles and Associated Risk Factors of Sars-Cov-2 Positive Patients Based on a
- 893 High-Throughput Testing Facility in India. Open Biol. 2021;11(6):200288. Epub 20210602. 894 https://doi.org/10.1098/rsob.200288. PubMed PMID: 34062097; PubMed Central PMCID:
- 895 PMC8169211.

896 Malagon-Rojas J, Gomez-Rendon C, Parra EL, Almentero J, Palma R, Lopez R, et al. Sars-94. 897 Cov-2 and Rt-Pcr in Asymptomatic Patients: Results of a Cohort of Workers at El Dorado International Airport in Bogota, 2020, Biomedica, 2020;40(Supl, 2):166-72, Epub 2020/11/06. 898 899 https://doi.org/10.7705/biomedica.5802. PubMed PMID: 33152200; PubMed Central PMCID: 900 7676845.

901 95. Maki G, Abdollah F, Dabaja A, Suleyman G. 462. Prevalence and Outcome of Asymptomatic 902 Procedural Patients with Covid-19 Infection. Open Forum Infectious Diseases. 903 2020;7(Supplement 1):S298-S. https://doi.org/10.1093/ofid/ofaa439.655.

904 96. Mahajan NN, Kesarwani SN, Shinde SS, Nayak A, Modi DN, Mahale SD, et al. Co-Infection 905 of Malaria and Dengue in Pregnant Women with Sars-Cov-2. Int J Gynaecol Obstet. 2020;151(3):459-62. Epub 2020/10/23. https://doi.org/10.1002/ijgo.13415. PubMed PMID: 906 907 33090458; PubMed Central PMCID: 7611276.

908 97. Machado CM, Kerbauy MN, Colturato I, Arcuri LJ, dos Santos ACF, Silva FR, et al. Clinical 909 Characteristics and Outcomes of Covid-19 in Hsct Recipients. Blood. 2020;136:19-. Epub 910 2021/08/03. https://doi.org/10.1182/blood-2020-141959. PubMed PMID: PMC8330389.

- 911 98. Luo L, Liu D, Liao X, Wu X, Jing Q, Zheng J, et al. Contact Settings and Risk for
- 912 Transmission in 3410 Close Contacts of Patients with Covid-19 in Guangzhou, China : A Prospective 913 Cohort Study. Ann Intern Med. 2020;173(11):879-87. Epub 2020/08/14.
- 914 https://doi.org/10.7326/m20-2671. PubMed PMID: 32790510; PubMed Central PMCID: 7506769.
- 99. London V, McLaren R, Jr., Atallah F, Cepeda C, McCalla S, Fisher N, et al. The Relationship 915
- 916 between Status at Presentation and Outcomes among Pregnant Women with Covid-19. Am J
- 917 Perinatol. 2020;37(10):991-4. Epub 2020/05/20. https://doi.org/10.1055/s-0040-1712164. PubMed
- 918 PMID: 32428964; PubMed Central PMCID: 7416203.
- 919 100. Lombardi A, Consonni D, Carugno M, Bozzi G, Mangioni D, Muscatello A, et al.
- 920 Characteristics of 1573 Healthcare Workers Who Underwent Nasopharyngeal Swab Testing for Sars-
- Cov-2 in Milan, Lombardy, Italy. Clin Microbiol Infect. 2020;26(10):1413 e9- e13. Epub 2020/06/23. 921
- 922 https://doi.org/10.1016/j.cmi.2020.06.013. PubMed PMID: 32569835; PubMed Central PMCID: 7305713. 923
- 924 101. Letizia AG, Ramos I, Obla A, Goforth C, Weir DL, Ge Y, et al. Sars-Cov-2 Transmission
- 925 among Marine Recruits During Ouarantine. N Engl J Med. 2020;383(25):2407-16. Epub 2020/11/12.
- 926 https://doi.org/10.1056/nejmoa2029717. PubMed PMID: 33176093; PubMed Central PMCID:
- 927 PMC7675690.

perpetuity. It is made available under a CC-BY 4.0 International license .

- 928 102. Lee JY, Hong SW, Hyun M, Park JS, Lee JH, Suh YS, et al. Epidemiological and Clinical
- 929 Characteristics of Coronavirus Disease 2019 in Daegu, South Korea. Int J Infect Dis. 2020;98:462-6. 930 Epub 2020/07/24. https://doi.org/10.1016/j.ijid.2020.07.017. PubMed PMID: 32702415; PubMed Central PMCID: 7371586. 931
- 932 Laws RL, Biraro S, Kirungi W, Gianetti B, Aibo D, Awor AC, et al. Coronavirus Disease 103.
- 933 2019 (Covid-19) Mitigation Efforts and Testing During an in-Person Training Event-Uganda, 12-29 October 2020. Clin Infect Dis. 2021;73(Suppl 1):S42-s4. https://doi.org/10.1093/cid/ciab331. 934
- PubMed PMID: 33912911; PubMed Central PMCID: PMC8135603. 935
- 936 104. Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Del Vecchio C, et al.
- 937 Suppression of a Sars-Cov-2 Outbreak in the Italian Municipality of Vo'. Nature.
- 2020;584(7821):425-9. Epub 2020/07/01. https://doi.org/10.1038/s41586-020-2488-1. PubMed 938 939 PMID: 32604404.
- 940 Lalani T, Lee TK, Laing ED, Ritter A, Cooper E, Lee M, et al. Sars-Cov-2 Infections and 105.
- 941 Serologic Responses among Military Personnel Deployed on the Usns Comfort to New York City
- During the Covid-19 Pandemic. Open Forum Infect Dis. 2021;8(2):ofaa654. Epub 20210123. 942
- https://doi.org/10.1093/ofid/ofaa654. PubMed PMID: 33553482; PubMed Central PMCID: 943
- 944 PMC7856331.
- 945 Ladhani SN, Jeffery-Smith A, Patel M, Janarthanan R, Fok J, Crawley-Boevey E, et al. High 106.
- 946 Prevalence of Sars-Cov-2 Antibodies in Care Homes Affected by Covid-19: Prospective Cohort
- Study, England. EClinicalMedicine. 2020;28:100597. Epub 2020/11/12. 947
- 948 https://doi.org/10.1016/j.eclinm.2020.100597. PubMed PMID: 33173854; PubMed Central PMCID: 949 7644437.
- 950 107. Kutsuna S, Suzuki T, Hayakawa K, Tsuzuki S, Asai Y, Suzuki T, et al. Sars-Cov-2 Screening
- 951 Test for Japanese Returnees from Wuhan, China, January 2020. Open Forum Infect Dis. 2020;7(7):ofaa243. Epub 2020/08/06. https://doi.org/10.1093/ofid/ofaa243. PubMed PMID: 952
- 953 32754627; PubMed Central PMCID: 7337761.
- 954 108. Kittang BR, Hofacker SV, Solheim SP, Kruger K, Loland KK, Jansen K. Outbreak of Covid-955 19 at Three Nursing Homes in Bergen. Tidsskr Nor Laegeforen. 2020;140(11). Epub 2020/08/21. 956 https://doi.org/10.4045/tidsskr.20.0405. PubMed PMID: 32815356.
- 957 109. Kirshblum SC, DeLauter G, Lopreiato MC, Pomeranz B, Dawson A, Hammerman S, et al.
- Screening Testing for Sars-Cov-2 Upon Admission to Rehabilitation Hospitals in a High Covid-19 958
- 959 Prevalence Community. PM R. 2020;12(10):1009-14. Epub 2020/07/24.
- 960 https://doi.org/10.1002/pmrj.12454. PubMed PMID: 32700434; PubMed Central PMCID: 7404891.
- 961 110. Khondaker T, Qader MA, Gosh K, Chowdhury GN, Ferdous T, Afroz S, et al. Clinical Profile and Outcome of Covid -19 in Children with Pre-Existing Renal Disease. J pediatric nephrol. 962 963 2020;9(1):1-6. https://doi.org/10.22037/jpn.v9i1.33008.
- 964 Kennelly SP, Dver AH, Noonan C, Martin R, Kennelly SM, Martin A, et al. Asymptomatic 111.
- Carriage Rates and Case Fatality of Sars-Cov-2 Infection in Residents and Staff in Irish Nursing 965 966 Homes. Age Ageing. 2021;50(1):49-54. Epub 2020/09/29. https://doi.org/10.1093/ageing/afaa220. PubMed PMID: 32986806; PubMed Central PMCID: 7543256. 967
- 968 112. Kasper MR, Geibe JR, Sears CL, Riegodedios AJ, Luse T, Von Thun AM, et al. An Outbreak
- of Covid-19 on an Aircraft Carrier. N Engl J Med. 2020;383(25):2417-26. Epub 2020/11/12. 969
- 970 https://doi.org/10.1056/nejmoa2019375. PubMed PMID: 33176077; PubMed Central PMCID:
- 971 7675688.

perpetuity. It is made available under a CC-BY 4.0 International license .

972 113. Jones A, Fialkowski V, Prinzing L, Trites J, Kelso P, Levine M. Assessment of Day-7

Postexposure Testing of Asymptomatic Contacts of Covid-19 Patients to Evaluate Early Release from 973

Quarantine - Vermont, May-November 2020. MMWR Morb Mortal Wkly Rep. 2021;70(1):12-3. 974 975 Epub 2021/01/08. http://dx.doi.org/10.15585/mmwr.mm7001a3. PubMed PMID: 33411700; PubMed

976 Central PMCID: 7790157.

977 Jeffery-Smith A, Dun-Campbell K, Janarthanan R, Fok J, Crawley-Boevey E, Vusirikala A, 114. et al. Infection and Transmission of Sars-Cov-2 in London Care Homes Reporting No Cases or 978 979 Outbreaks of Covid-19: Prospective Observational Cohort Study, England 2020. Lancet Reg Health 980 Eur. 2021;3:100038. Epub 20210122. https://doi.org/10.1016/j.lanepe.2021.100038. PubMed PMID: 981 33870248; PubMed Central PMCID: PMC7826003.

982 Isoldi S, Mallardo S, Marcellino A, Bloise S, Dilillo A, Iorfida D, et al. The Comprehensive 115. 983 Clinic, Laboratory, and Instrumental Evaluation of Children with Covid-19: A 6-Months Prospective 984 Study. J Med Virol. 2021;93(5):3122-32. Epub 20210216. https://doi.org/10.1002/jmv.26871. 985 PubMed PMID: 33570199; PubMed Central PMCID: PMC8014060.

Hwang CE, Kussman A, Christle JW, Froelicher V, Wheeler MT, Moneghetti KJ, Findings 986 116. from Cardiovascular Evaluation of National Collegiate Athletic Association Division I Collegiate 987 988 Student-Athletes after Asymptomatic or Mildly Symptomatic Sars-Cov-2 Infection. Clin J Sport Med. 2022;32(2):103-7. https://doi.org/10.1097/jsm.000000000000954. PubMed PMID: 34173780. 989

990 Hussain A, Satti L, Hanif F, Shoaib M, Ghauri MA, Khan Niazi GA, et al. Clinical and 117. 991 Virological Course of Sars-Cov 2 Infected Patients in a Tertiary Care Hospital in Pakistan. J Ayub 992 Med Coll Abbottabad. 2020;32(Suppl 1)(4):S602-s6. https://pubmed.ncbi.nlm.nih.gov/33754515/.

993 PubMed PMID: 33754515; PubMed Central PMCID: 33754515.

994 118. Hurst JH, Heston SM, Chambers HN, Cunningham HM, Price MJ, Suarez L, et al. Severe 995 Acute Respiratory Syndrome Coronavirus 2 Infections among Children in the Biospecimens from 996 Respiratory Virus-Exposed Kids (Brave Kids) Study. Clinical Infectious Diseases. 2021;73(9):e2875-997 e82. https://doi.org/10.1093/cid/ciaa1693.

998 119. Hogan CA, Gombar S, Wang H, Roltgen K, Shi RZ, Holubar M, et al. Large-Scale Testing of 999 Asymptomatic Healthcare Personnel for Severe Acute Respiratory Syndrome Coronavirus 2. Emerg 1000 Infect Dis. 2021;27(1). Epub 2020/12/02. https://doi.org/10.3201/eid2701.203892. PubMed PMID: 1001 33256889; PubMed Central PMCID: PMC7774535.

1002 Hoehl S, Rabenau H, Berger A, Kortenbusch M, Cinatl J, Bojkova D, et al. Evidence of Sars-120. 1003 Cov-2 Infection in Returning Travelers from Wuhan, China. N Engl J Med. 2020;382(13):1278-80. 1004 Epub 2020/02/19. https://doi.org/10.1056/nejmc2001899. PubMed PMID: 32069388; PubMed 1005 Central PMCID: 7121749.

1006 Hijnen D, Marzano AV, Eyerich K, GeurtsvanKessel C, Gimenez-Arnau AM, Joly P, et al. 121. 1007 Sars-Cov-2 Transmission from Presymptomatic Meeting Attendee, Germany. Emerg Infect Dis. 1008 2020;26(8):1935-7. Epub 2020/05/12. https://doi.org/10.3201/eid2608.201235. PubMed PMID: 1009 32392125; PubMed Central PMCID: 7392453.

1010 Hcini N, Maamri F, Picone O, Carod JF, Lambert V, Mathieu M, et al. Maternal, Fetal and 122. 1011 Neonatal Outcomes of Large Series of Sars-Cov-2 Positive Pregnancies in Peripartum Period: A Single-Center Prospective Comparative Study. Eur J Obstet Gynecol Reprod Biol. 2021;257:11-8. 1012 1013 Epub 2020/12/15. https://doi.org/10.1016/j.ejogrb.2020.11.068. PubMed PMID: 33310656; PubMed Central PMCID: 7705341. 1014

1015 Harada S, Uno S, Ando T, Iida M, Takano Y, Ishibashi Y, et al. Control of a Nosocomial 123. 1016 Outbreak of Covid-19 in a University Hospital. Open Forum Infect Dis. 2020;7(12):ofaa512. Epub

1017 2020/12/18. <u>https://doi.org/10.1093/ofid/ofaa512</u>. PubMed PMID: 33330740; PubMed Central
 1018 PMCID: 7665726.

1019 124. Han X, Wei X, Alwalid O, Cao Y, Li Y, Wang L, et al. Severe Acute Respiratory Syndrome
1020 Coronavirus 2 among Asymptomatic Workers Screened for Work Resumption, China. Emerg Infect
1021 Dis. 2020;26(9). Epub 2020/06/20. <u>https://doi.org/10.3201/eid2609.201848</u>. PubMed PMID:
1022 32553070; PubMed Central PMCID: 7454110.

1023 125. Hall VJ, Foulkes S, Charlett A, Atti A, Monk EJM, Simmons R, et al. Sars-Cov-2 Infection
1024 Rates of Antibody-Positive Compared with Antibody-Negative Health-Care Workers in England: A
1025 Large, Multicentre, Prospective Cohort Study (Siren). Lancet. 2021;397(10283):1459-69. Epub
1026 20210409. <u>https://doi.org/10.1016/s0140-6736(21)00675-9</u>. PubMed PMID: 33844963; PubMed
1027 Central PMCID: PMC8040523.

1028 126. Haidar G, Ayres A, King WC, McDonald M, Wells A, Mitchell SL, et al. Preprocedural Sars1029 Cov-2 Testing to Sustain Medically Needed Health Care Delivery During the Covid-19 Pandemic: A
1030 Prospective Observational Study. Open Forum Infectious Diseases. 2021;8(2).
1031 https://doi.org/10.1093/ofid/ofab022.

1032 127. Grijalva CG, Rolfes MA, Zhu Y, McLean HQ, Hanson KE, Belongia EA, et al. Transmission
 1033 of Sars-Cov-2 Infections in Households - Tennessee and Wisconsin, April-September 2020. MMWR

1034 Morb Mortal Wkly Rep. 2020;69(44):1631-4. Epub 2020/11/06.

1035 <u>http://dx.doi.org/10.15585/mmwr.mm6944e1</u>. PubMed PMID: 33151916; PubMed Central PMCID: 1036 7643897.

1037 128. Green R, Tulloch JSP, Tunnah C, Coffey E, Lawrenson K, Fox A, et al. Covid-19 Testing in
1038 Outbreak-Free Care Homes: What Are the Public Health Benefits? J Hosp Infect. 2021;111:89-95.
1039 Epub 2021/01/17. <u>https://doi.org/10.1016/j.jhin.2020.12.024</u>. PubMed PMID: 33453349; PubMed
1040 Central PMCID: 7837210.

1041 129. Graham NSN, Junghans C, Downes R, Sendall C, Lai H, McKirdy A, et al. Sars-Cov-2
1042 Infection, Clinical Features and Outcome of Covid-19 in United Kingdom Nursing Homes. J Infect.
1043 2020;81(3):411-9. Epub 2020/06/07. <u>https://doi.org/10.1016/j.jinf.2020.05.073</u>. PubMed PMID:
1044 32504743; PubMed Central PMCID: 7836316.

1045 130. Ghinai I, Davis ES, Mayer S, Toews KA, Huggett TD, Snow-Hill N, et al. Risk Factors for
1046 Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Homeless Shelters in Chicago,
1047 Illinois-March-May, 2020. Open Forum Infect Dis. 2020;7(11):ofaa477. Epub 2020/12/03.
1048 https://doi.org/10.1093/ofid/ofaa477. PubMed PMID: 33263069; PubMed Central PMCID: 7665740.

1049 131. Gettings JR, Gold JAW, Kimball A, Forsberg K, Scott C, Uehara A, et al. Severe Acute 1050 Respiratory Syndrome Coronavirus 2 Transmission in a Georgia School District-United States,

1051 December 2020-January 2021. Clin Infect Dis. 2022;74(2):319-26.

1052 <u>https://doi.org/10.1093/cid/ciab332</u>. PubMed PMID: 33864375; PubMed Central PMCID:
 1053 PMC8083290.

1054 132. Garibaldi PMM, Ferreira NN, Moraes GR, Moura JC, Espósito DLA, Volpe GJ, et al.

1055 Efficacy of Covid-19 Outbreak Management in a Skilled Nursing Facility Based on Serial Testing for

Early Detection and Control. Braz J Infect Dis. 2021;25(2):101570. Epub 20210323.

https://doi.org/10.1016/j.bjid.2021.101570. PubMed PMID: 33773990; PubMed Central PMCID:
 PMC7985963.

1059 133. Fisher MJ, Psevdos G. Asymptomatic Sars-Cov-2 Infection Following First Dose Mrna-1273
1060 Covid-19 Vaccine in a Veterans Affairs Long Term Care Facility. Am J Infect Control.

- 2021;49(9):1210-1. Epub 20210625. <u>https://doi.org/10.1016/j.ajic.2021.06.010</u>. PubMed PMID:
 34175364; PubMed Central PMCID: PMC8225993.
- 1063 134. Ferreira VH, Chruscinski A, Kulasingam V, Pugh TJ, Dus T, Wouters B, et al. Prospective
 1064 Observational Study and Serosurvey of Sars-Cov-2 Infection in Asymptomatic Healthcare Workers at
 1065 a Canadian Tertiary Care Center. PLoS One. 2021;16(2):e0247258. Epub 2021/02/17.
 1066 <u>https://doi.org/10.1371/journal.pone.0247258</u>. PubMed PMID: 33592074; PubMed Central PMCID:
 1067 7886177.
- 1068 135. Fakhim H, Nasri E, Aboutalebian S, Gholipour S, Nikaeen M, Vaezi A, et al. Asymptomatic
 1069 Carriers of Coronavirus Disease 2019 among Healthcare Workers in Isfahan, Iran. Future Virology.
 1070 2021;16(2):93-8. https://dx.doi.org/10.2217%2Ffvl-2020-0224.
- 1071 136. Eythorsson E, Helgason D, Ingvarsson RF, Bjornsson HK, Olafsdottir LB, Bjarnadottir V, et
 1072 al. Clinical Spectrum of Coronavirus Disease 2019 in Iceland: Population Based Cohort Study. BMJ.
 1073 2020;371:m4529. Epub 2020/12/04. <u>https://doi.org/10.1136/bmj.m4529</u>. PubMed PMID: 33268329;
 1074 PubMed Central PMCID: 7708618.
- 1075 137. Esteban I, Bergero G, Alves C, Bronstein M, Ziegler V, Wood C, et al. Asymptomatic Covid1076 19 in the Elderly: Dementia and Viral Clearance as Risk Factors for Disease Progression. TP92
 1077 TP092 CLINICAL ADVANCES IN SARS-COV-2 AND COVID-19. 2021:A3826-A.
 1078 https://doi.org/10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A3826.
- 1079 138. Edelstein M, Obi C, Chand M, Hopkins S, Brown K, Ramsay M. Sars-Cov-2 Infection in
 1080 London, England: Changes to Community Point Prevalence around Lockdown Time, March-May
- 1081 2020. J Epidemiol Community Health. 2021;75(2):185-8. Epub 2020/10/03.
- 1082 <u>https://doi.org/10.1136/jech-2020-214730</u>. PubMed PMID: 33004659; PubMed Central PMCID:
 1083 7815898.
- 1084 139. Dora AV, Winnett A, Jatt LP, Davar K, Watanabe M, Sohn L, et al. Universal and Serial
 1085 Laboratory Testing for Sars-Cov-2 at a Long-Term Care Skilled Nursing Facility for Veterans Los
 1086 Angeles, California, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(21):651-5. Epub 2020/05/29.
 1087 <u>https://doi.org/10.15585/mmwr.mm6921e1</u>. PubMed PMID: 32463809; PubMed Central PMCID:
 1088 7269604.
- 1089 140. Danis K, Epaulard O, Benet T, Gaymard A, Campoy S, Bothelo-Nevers E, et al. Cluster of
 1090 Coronavirus Disease 2019 (Covid-19) in the French Alps, 2020. Clin Infect Dis. 2020. Epub
 1091 2020/04/12. <u>https://doi.org/10.1093/cid/ciaa424</u>. PubMed PMID: 32277759; PubMed Central
 1092 PMCID: 7184384.
- 1093 141. Corcorran MA, Olin S, Rani G, Nasenbeny K, Constantino-Shor C, Holmes C, et al.
 1094 Prolonged Persistence of Pcr-Detectable Virus During an Outbreak of Sars-Cov-2 in an Inpatient
 1095 Geriatric Psychiatry Unit in King County, Washington. Am J Infect Control. 2021;49(3):293-8. Epub
 1096 2020/08/23. <u>https://doi.org/10.1016/j.ajic.2020.08.025</u>. PubMed PMID: 32827597; PubMed Central
 1097 PMCID: 7438365.
- 142. Cheng HY, Jian SW, Liu DP, Ng TC, Huang WT, Lin HH, et al. Contact Tracing Assessment
 of Covid-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods before and
 after Symptom Onset. JAMA Intern Med. 2020;180(9):1156-63. Epub 2020/05/02.
 https://doi.org/10.1001/jamainternmed.2020.2020. PubMed PMID: 32356867; PubMed Central
 PMCID: 7195694.
- 1103 143. Chang L, Zhao L, Gong H, Wang L, Wang L. Severe Acute Respiratory Syndrome
 1104 Coronavirus 2 Rna Detected in Blood Donations. Emerg Infect Dis. 2020;26(7):1631-3. Epub

- It is made available under a CC-BT 4.0 International license .
- 1105 2020/04/04. <u>https://doi.org/10.3201/eid2607.200839</u>. PubMed PMID: 32243255; PubMed Central
 1106 PMCID: 7323524.
- 144. Chamie G, Marquez C, Crawford E, Peng J, Petersen M, Schwab D, et al. Community
 Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Disproportionately Affects the
 Latinx Population During Shelter-in-Place in San Francisco. Clin Infect Dis. 2021;73(Suppl 2):S127S35. Epub 2020/08/22. <u>https://doi.org/10.1093/cid/ciaa1234</u>. PubMed PMID: 32821935; PubMed
 Central PMCID: 7499499.
- 1112 145. Cariani L, Orena BS, Ambrogi F, Gambazza S, Maraschini A, Dodaro A, et al. Time Length
- 1113 of Negativization and Cycle Threshold Values in 182 Healthcare Workers with Covid-19 in Milan,
- 1114 Italy: An Observational Cohort Study. Int J Environ Res Public Health. 2020;17(15). Epub
 1115 2020/07/29. <u>https://doi.org/10.3390/ijerph17155313</u>. PubMed PMID: 32718008; PubMed Central
 1116 PMCUD 7422021
- 1116 PMCID: 7432921.
- 1117 146. Cardillo L, de Martinis C, Viscardi M, Esposito C, Sannino E, Lucibelli G, et al. Sars-Cov-2
- 1118 Quantitative Real Time Pcr and Viral Loads Analysis among Asymptomatic and Symptomatic
- 1119 Patients: An Observational Study on an Outbreak in Two Nursing Facilities in Campania Region
- **1120** (Southern Italy). Infect Agent Cancer. 2021;16(1):45. Epub 20210622.
- https://doi.org/10.1186/s13027-021-00388-x. PubMed PMID: 34158108; PubMed Central PMCID:
 PMC8218569.
- 1123 147. Cao S, Gan Y, Wang C, Bachmann M, Wei S, Gong J, et al. Post-Lockdown Sars-Cov-2
- Nucleic Acid Screening in Nearly Ten Million Residents of Wuhan, China. Nat Commun.
 2020;11(1):5917. Epub 2020/11/22. <u>https://doi.org/10.1038/s41467-020-19802-w.</u> PubMed PMID:
- 1126 33219229; PubMed Central PMCID: 7679396.
- 148. Brandstetter S, Roth S, Harner S, Buntrock-Dopke H, Toncheva AA, Borchers N, et al.
 Symptoms and Immunoglobulin Development in Hospital Staff Exposed to a Sars-Cov-2 Outbreak.
 Pediatr Allergy Immunol. 2020;31(7):841-7. Epub 2020/05/16. <u>https://doi.org/10.1111/pai.13278</u>.
 PubMed PMID: 32413201.
- 149. Bohmer MM, Buchholz U, Corman VM, Hoch M, Katz K, Marosevic DV, et al. Investigation
 of a Covid-19 Outbreak in Germany Resulting from a Single Travel-Associated Primary Case: A Case
 Series. Lancet Infect Dis. 2020;20(8):920-8. Epub 2020/05/19. <u>https://doi.org/10.1016/s1473-</u>
 3099(20)30314-5. PubMed PMID: 32422201; PubMed Central PMCID: 7228725.
- 1135 150. Bogani G, Ditto A, Bosio S, Brusadelli C, Raspagliesi F. Cancer Patients Affected by Covid1136 19: Experience from Milan, Lombardy. Gynecol Oncol. 2020;158(2):262-5. Epub 2020/06/15.
 1137 <u>https://doi.org/10.1016/j.ygyno.2020.06.161</u>. PubMed PMID: 32534808; PubMed Central PMCID:
 1138 7286266.
- 1139 151. Blain H, Gamon L, Tuaillon E, Pisoni A, Giacosa N, Albrand M, et al. Atypical Symptoms,
- 1140 Sars-Cov-2 Test Results and Immunisation Rates in 456 Residents from Eight Nursing Homes Facing
- 1141 a Covid-19 Outbreak. Age Ageing. 2021;50(3):641-8. <u>https://doi.org/10.1093/ageing/afab050</u>.
- 1142PubMed PMID: 33620381; PubMed Central PMCID: PMC7929417.
- 1143 152. Berghoff AS, Gansterer M, Bathke AC, Trutschnig W, Hungerlander P, Berger JM, et al.
- Sars-Cov-2 Testing in Patients with Cancer Treated at a Tertiary Care Hospital During the Covid-19
 Pandemic. J Clin Oncol. 2020;38(30):3547-54. Epub 2020/08/17.
- 1146 <u>https://doi.org/10.1200/jco.20.01442</u>. PubMed PMID: 32795227; PubMed Central PMCID: 7571795.
- 1147 153. Bender WR, Hirshberg A, Coutifaris P, Acker AL, Srinivas SK. Universal Testing for Severe
- 1148 Acute Respiratory Syndrome Coronavirus 2 in 2 Philadelphia Hospitals: Carrier Prevalence and
- 1149 Symptom Development over 2 Weeks. Am J Obstet Gynecol MFM. 2020;2(4):100226. Epub

- 1150 2020/09/22. https://doi.org/10.1016/j.ajogmf.2020.100226. PubMed PMID: 32954248; PubMed 1151 Central PMCID: 7485442.
- Beiting KJ, Huisingh-Scheetz M, Walker J, Graupner J, Martinchek M, Thompson K, et al. 1152 154. 1153 Management and Outcomes of a Covid-19 Outbreak in a Nursing Home with Predominantly Black Residents. J Am Geriatr Soc. 2021;69(5):1155-65. Epub 20210324. 1154
- 1155 https://doi.org/10.1111/jgs.17126. PubMed PMID: 33739444; PubMed Central PMCID:
- 1156 PMC8218575.
- 1157 155. Balestrini S, Koepp MJ, Gandhi S, Rickman HM, Shin GY, Houlihan CF, et al. Clinical 1158 Outcomes of Covid-19 in Long-Term Care Facilities for People with Epilepsy. Epilepsy Behav. 1159 2021;115:107602. Epub 2020/12/07. https://doi.org/10.1016/j.yebeh.2020.107602. PubMed PMID: 1160 33279440; PubMed Central PMCID: 7643621.
- 1161 156. Aslam A, Singh J, Robilotti E, Chow K, Bist T, Reidy-Lagunes D, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Surveillance and Exposure in the Perioperative Setting with 1162 1163 Universal Testing and Personal Protective Equipment Policies. Clin Infect Dis. 2021;73(9):e3013-e8. Epub 2020/10/23. https://doi.org/10.1093/cid/ciaa1607. PubMed PMID: 33090210: PubMed Central 1164 1165 PMCID: 7665395.
- Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic 1166 157. Sars-Cov-2 Infections and Transmission in a Skilled Nursing Facility. N Engl J Med. 1167 1168 2020;382(22):2081-90. Epub 2020/04/25. https://doi.org/10.1056/NEJMoa2008457. PubMed PMID:
- 32329971; PubMed Central PMCID: 7200056. 1169
- 1170 Andrikopoulou M, Madden N, Wen T, Aubey JJ, Aziz A, Baptiste CD, et al. Symptoms and 158. Critical Illness among Obstetric Patients with Coronavirus Disease 2019 (Covid-19) Infection. Obstet 1171 Gynecol. 2020;136(2):291-9. Epub 2020/05/28. https://doi.org/10.1097/aog.00000000003996. 1172 1173 PubMed PMID: 32459701.
- 1174 Alshahrani MS, Alnimr A, Alnassri S, Alfarag S, Aljehani Y, Alabdali M. Prevalence of the 159. 1175 Sars-Cov-2 Infection among Post-Quarantine Healthcare Workers. J Multidiscip Healthc. 1176 2020;13:1927-36. Epub 2020/12/29. https://doi.org/10.2147/jmdh.s279469. PubMed PMID: 1177 33363380; PubMed Central PMCID: 7752650.
- 1178 160. Almazeedi S, Al-Youha S, Jamal MH, Al-Haddad M, Al-Muhaini A, Al-Ghimlas F, et al. 1179 Characteristics, Risk Factors and Outcomes among the First Consecutive 1096 Patients Diagnosed 1180 with Covid-19 in Kuwait. EClinicalMedicine. 2020;24:100448. Epub 2020/08/09. 1181 https://doi.org/10.1016/j.eclinm.2020.100448. PubMed PMID: 32766546; PubMed Central PMCID: 1182 7335246.
- 1183 161. Al-Qahtani M, AlAli S, AbdulRahman A, Salman Alsayyad A, Otoom S, Atkin SL. The 1184 Prevalence of Asymptomatic and Symptomatic Covid-19 in a Cohort of Quarantined Subjects. Int J 1185 Infect Dis. 2021;102:285-8. Epub 2020/11/07. https://doi.org/10.1016/j.ijid.2020.10.091. PubMed
- 1186 PMID: 33157290; PubMed Central PMCID: 7607262.
- 1187 Adhikari EH, Moreno W, Zofkie AC, MacDonald L, McIntire DD, Collins RRJ, et al. 162.
- 1188 Pregnancy Outcomes among Women with and without Severe Acute Respiratory Syndrome
- Coronavirus 2 Infection. JAMA Netw Open. 2020;3(11):e2029256. Epub 2020/11/20. 1189
- https://doi.org/10.1001/jamanetworkopen.2020.29256. PubMed PMID: 33211113; PubMed Central 1190 1191 PMCID: 7677755.
- 1192 Abraha HE, Gessesse Z, Gebrecherkos T, Kebede Y, Weldegiargis AW, Tequare MH, et al. 163. 1193 Clinical Features and Risk Factors Associated with Morbidity and Mortality among Patients with
- 1194 Covid-19 in Northern Ethiopia. Int J Infect Dis. 2021;105:776-83. Epub 20210316.

- https://doi.org/10.1016/j.ijid.2021.03.037. PubMed PMID: 33741488; PubMed Central PMCID:
 PMC7962557.
- 1197 164. AbdulRahman A, AlAli S, Yaghi O, Shabaan M, Otoom S, Atkin SL, et al. Covid-19 and
 1198 Sickle Cell Disease in Bahrain. Int J Infect Dis. 2020;101:14-6. Epub 2020/09/28.
 1100 https://doi.org/10.1016/j.jijid.2020.00.1422. PubMed PMID: 22080556; PubMed Control PMCID;
- <u>https://doi.org/10.1016/j.ijid.2020.09.1433</u>. PubMed PMID: 32980556; PubMed Central PMCID:
 7833176.
- 1201 165. Wu P, Liu F, Chang Z, Lin Y, Ren M, Zheng C, et al. Assessing Asymptomatic,
- Presymptomatic, and Symptomatic Transmission Risk of Severe Acute Respiratory Syndrome
 Coronavirus 2. Clin Infect Dis. 2021;73(6):e1314-e20. <u>https://doi.org/10.1093/cid/ciab271</u>. PubMed
 PMID: 33772573; PubMed Central PMCID: PMC8083716.
- 1205 166. Luo L, Liu D, Liao X-l, Wu X-b, Jing Q-l, Zheng J-z, et al. Modes of Contact and Risk of
 1206 Transmission in Covid-19 among Close Contacts. bioRxiv [Preprint]. 2020.
 1207 https://doi.org/10.1101/2020.03.24.20042606.
- 2020/10/10. <u>https://doi.org/10.3201/eid2611.202263</u>. PubMed PMID: 33035448; PubMed Central
 PMCID: 7588541.
- 168. Bender JK, Brandl M, Höhle M, Buchholz U, Zeitlmann N. Analysis of Asymptomatic and
 Presymptomatic Transmission in Sars-Cov-2 Outbreak, Germany, 2020. Emerging infectious
 diseases. 2021;27(4):1159-63. Epub 2021/02/18. <u>https://dx.doi.org/10.3201%2Feid2704.204576</u>.
 PubMed PMID: 33600301.
- 1216 169. Zhang W. Estimating the Presymptomatic Transmission of Covid19 Using Incubation Period
 1217 and Serial Interval Data. bioRxiv [Preprint]. 2020. <u>https://doi.org/10.1101/2020.04.02.20051318</u>.
- 1218 170. Tindale LC, Stockdale JE, Coombe M, Garlock ES, Lau WYV, Saraswat M, et al. Evidence
- for Transmission of Covid-19 Prior to Symptom Onset Elife. 2020;9. Epub 2020/06/23.
 https://doi.org/10.7554/elife.57149. PubMed PMID: 32568070; PubMed Central PMCID: 7386904.
- 1221 171. Tan J, Ge Y, Martinez L, Sun J, Li C, Westbrook A, et al. Transmission Roles of 1222 Symptomatic and Asymptomatic Covid-19 Cases: A Modeling Study. medRxiv [Preprint].
- 1223 2021:2021.05.11.21257060. <u>https://doi.org/10.1101/2021.05.11.21257060</u>.
- 1224 172. Sun K, Wang W, Gao L, Wang Y, Luo K, Ren L, et al. Transmission Heterogeneities,
- Kinetics, and Controllability of Sars-Cov-2. Science. 2021;371(6526). Epub 2020/11/26.
 https://doi.org/10.1126/science.abe2424. PubMed PMID: 33234698; PubMed Central PMCID:
- 1227 7857413.
- 173. Ren X, Li Y, Yang X, Li Z, Cui J, Zhu A, et al. Evidence for Pre-Symptomatic Transmission of Coronavirus Disease 2019 (Covid-19) in China. Influenza Other Respir Viruses. 2021;15(1):19-26.
 Epub 2020/08/09. <u>https://doi.org/10.1111/irv.12787</u>. PubMed PMID: 32767657; PubMed Central PMCID: 7436222.
- 174. Peak CM, Kahn R, Grad YH, Childs LM, Li R, Lipsitch M, et al. Individual Quarantine
 Versus Active Monitoring of Contacts for the Mitigation of Covid-19: A Modelling Study. Lancet
 Infect Dis. 2020;20(9):1025-33. Epub 2020/05/24. <u>https://doi.org/10.1016/s1473-3099(20)30361-3</u>.
 PubMed PMID: 32445710; PubMed Central PMCID: 7239635.
- 1236 175. Moghadas SM, Fitzpatrick MC, Sah P, Pandey A, Shoukat A, Singer BH, et al. The
 1237 Implications of Silent Transmission for the Control of Covid-19 Outbreaks. Proc Natl Acad Sci U S

- A. 2020;117(30):17513-5. Epub 2020/07/08. <u>https://doi.org/10.1073/pnas.2008373117</u>. PubMed
 PMID: 32632012; PubMed Central PMCID: 7395516.
- 1240 176. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal Dynamics in Viral
 1241 Shedding and Transmissibility of Covid-19. Nat Med. 2020;26(5):672-5. Epub 2020/04/17.
 1242 https://doi.org/10.1038/s41591-020-0869-5. PubMed PMID: 32296168.
- 1243 177. Emery JC, Russell TW, Liu Y, Hellewell J, Pearson CA, Group CC-W, et al. The
 1244 Contribution of Asymptomatic Sars-Cov-2 Infections to Transmission on the Diamond Princess
 1245 Cruise Ship. Elife. 2020;9. Epub 2020/08/25. <u>https://doi.org/10.7554/elife.58699</u>. PubMed PMID:
 1246 32831176; PubMed Central PMCID: 7527238.
- 1247 178. Chun JY, Baek G, Kim Y. Transmission Onset Distribution of Covid-19. Int J Infect Dis.
 1248 2020;99:403-7. Epub 2020/08/11. <u>https://doi.org/10.1016/j.ijid.2020.07.075</u>. PubMed PMID:
 1249 32771633; PubMed Central PMCID: 7409940.
- 179. Bushman M, Worby C, Chang HH, Kraemer MUG, Hanage WP. Transmission of Sars-Cov-2
 before and after Symptom Onset: Impact of Nonpharmaceutical Interventions in China. Eur J
 Epidemiol. 2021;36(4):429-39. Epub 2021/04/22. <u>https://doi.org/10.1007/s10654-021-00746-4</u>.
 PubMed PMID: 33881667; PubMed Central PMCID: 8058147.
- 1254 180. Chau NVV, Thanh Lam V, Thanh Dung N, Yen LM, Minh NNQ, Hung LM, et al. The
 1255 Natural History and Transmission Potential of Asymptomatic Sars-Cov-2 Infection. Clin Infect Dis.
 1256 2020. https://doi.org/10.1093/cid/ciaa711.
- 1257 181. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-Negative
 1258 Rate of Reverse Transcriptase Polymerase Chain Reaction-Based Sars-Cov-2 Tests by Time since
 1259 Exposure. Ann Intern Med. 2020. Epub 2020/05/19. <u>https://doi.org/10.7326/M20-1495</u>. PubMed
 1260 PMID: 32422057; PubMed Central PMCID: 7240870.
- 1261 182. Qiu X, Nergiz AI, Maraolo AE, Bogoch, II, Low N, Cevik M. The Role of Asymptomatic and
 1262 Pre-Symptomatic Infection in Sars-Cov-2 Transmission-a Living Systematic Review. Clin Microbiol
 1263 Infect. 2021;27(4):511-9. Epub 20210121. <u>https://doi.org/10.1016/j.cmi.2021.01.011</u>. PubMed
 1264 PMID: 33484843; PubMed Central PMCID: 7825872.
- 1265 183. Goguet E, Powers JH, III, Olsen CH, Tribble DR, Davies J, Illinik L, et al. Prospective
 1266 Assessment of Symptoms to Evaluate Asymptomatic Sars-Cov-2 Infections in a Cohort of Health
 1267 Care Workers. Open Forum Infectious Diseases. 2022;9(3):ofac030.
 1268 https://doi.org/10.1093/ofid/ofac030.
- 1269 184. Madewell ZJ, Yang Y, Longini IM, Jr, Halloran ME, Dean NE. Household Transmission of
 1270 Sars-Cov-2: A Systematic Review and Meta-Analysis. JAMA Network Open. 2020;3(12):e20317561271 e. <u>https://doi.org/10.1001/jamanetworkopen.2020.31756</u>.
- 1272 185. Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic Transmission of Sars-
- 1273 Cov-2 Singapore, January 23-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(14):411-5.
- 1274 Epub 2020/04/10. <u>http://dx.doi.org/10.15585/mmwr.mm6914e1</u>. PubMed PMID: 32271722; PubMed
- **1275** Central PMCID: 7147908
- 1276 186. Hoffmann F, Eggers D, Pieper D, Zeeb H, Allers K. An Observational Study Found Large
- 1277 Methodological Heterogeneity in Systematic Reviews Addressing Prevalence and Cumulative
- 1278 Incidence. J Clin Epidemiol. 2020;119:92-9. Epub 20191203.
- 1279 <u>https://doi.org/10.1016/j.jclinepi.2019.12.003</u>. PubMed PMID: 31809847.

- 1280 187. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and Immunological Assessment of Asymptomatic Sars-Cov-2 Infections. Nat Med. 2020. Epub 2020/06/20. 1281 1282 https://doi.org/10.1038/s41591-020-0965-6. PubMed PMID: 32555424.

Karim SSA, Karim OA. Omicron Sars-Cov-2 Variant: A New Chapter in the Covid-19 1283 188. 1284 Pandemic. Lancet. 2021;398(10317):2126-8. Epub 20211203. https://doi.org/10.1016/s0140-6736(21)02758-6. PubMed PMID: 34871545; PubMed Central PMCID: 8640673. 1285

- Sharma RP, Gautam S, Sharma P, Singh R, Sharma H, Parsoya D, et al. Clinico 1286 189.
- 1287 Epidemiological Profile of Omicron Variant of Sars Cov2 in Rajasthan. medRxiv [Preprint]. 2022:2022.02.11.22270698. https://doi.org/10.1101/2022.02.11.22270698. 1288

1289 190. Brandal LT, MacDonald E, Veneti L, Ravlo T, Lange H, Naseer U, et al. Outbreak Caused by the Sars-Cov-2 Omicron Variant in Norway, November to December 2021. Euro Surveill. 1290 1291 2021;26(50). https://doi.org/10.2807/1560-7917.es.2021.26.50.2101147. PubMed PMID: 34915975; 1292 PubMed Central PMCID: PMC8728491.

- The Guardian Dismay as Funding for Uk's 'World-Beating' Covid Trackers Is Axed 1293 191.
- 1294 12.03.2022 [Access Date: 17.03.2022]. Available from:
- https://www.theguardian.com/world/2022/mar/12/dismay-as-funding-for-uks-world-beating-covid-1295 trackers-is-axed. 1296
- 1297

Acknowledgements 1298

- 1299 We are very grateful to Dianne Egli-Gany, Michel J. Counotte, Stefanie Hossmann who were part of our original core team of reviewers and contributed to the first three versions of this living systematic 1300
- review. 1301

Author contributions 1302

- Conceptualization: Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Nicola Low 1303
- 1304 Data Curation: Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Hira Imeri, Lucia Araujo-

1305 Chaveron, Ingrid Arevalo-Rodriguez, Agustín Ciapponi, Muge Cevik, Muhammad Irfanul Alam,

- 1306 Kaspar Meili, Eric A. Meyerowitz, Nirmala Prajapati, Xueting Qiu, Aaron Richterman, William 1307 Gildardo Robles-Rodríguez, Shabnam Thapa, Ivan Zhelyazkov.
- 1308 Data extraction: Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Eric A. Meyerowitz, 1309 Aaron Richterman, Nirmala Prajapati, William Gildardo Robles-Rodríguez, Nicola Low
- 1310 Risk of Bias assessment: Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Ingrid Arevalo-
- 1311 Rodriguez, Anthony Hauser, Aaron Richterman, Nirmala Prajapati, William Gildardo Robles-
- Rodríguez, Nicola Low 1312
- Formal Analysis: Leonie Heron, Georgia Salanti, Nicola Low 1313
- Methodology: Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Anthony Hauser, Georgia 1314 1315 Salanti, Nicola Low
- Project Administration: Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Hira Imeri 1316
- Supervision: Georgia Salanti, Nicola Low 1317
- Validation: Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Hira Imeri, Lucia Araujo-1318
- 1319 Chaveron, Ingrid Arevalo-Rodriguez, Agustín Ciapponi, Muge Cevik, Muhammad Irfanul Alam,
- 1320 Kaspar Meili, Eric A. Meyerowitz, Nirmala Prajapati, Xueting Qiu, Aaron Richterman, William
- 1321 Gildardo Robles-Rodríguez, Shabnam Thapa, Ivan Zhelyazkov, Anthony Hauser, Nicola Low

- 1322 Writing-Original Draft: Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Nicola Low
- Writing- review & editing: Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Hira Imeri, 1323
- 1324 Lucia Araujo-Chaveron, Ingrid Arevalo-Rodriguez, Agustín Ciapponi, Muge Cevik, Muhammad
- 1325 Irfanul Alam, Kaspar Meili, Eric A. Meyerowitz, Nirmala Prajapati, Xueting Qiu, Aaron Richterman,
- 1326 William Gildardo Robles-Rodríguez, Shabnam Thapa, Ivan Zhelyazkov, Anthony Hauser, Georgia
- 1327 Salanti, Nicola Low.
- Funding 1328
- 1329 Funding was received from the Swiss National Science Foundation (320030 176233, to
- NL), http://www.snf.ch/en/Pages/default.aspx; European Union Horizon 2020 research 1330
- 1331 and innovation programme (101003688, to NL), https://ec.europa.eu/programmes/horizon2020/en;
- Swiss government excellence Scholarship (2019.0774, to 1332
- 1333 DBG https://www.sbfi.admin.ch/sbfi/en/home/education/scholarships-and-grants/swiss-government-
- excellence-scholarships.html and the Swiss School of Public Health Global P3HS stipend (to 1334
- 1335 DBG), https://ssphplus.ch/en/ globalp3hs/.
- The funders had no role in study design, data collection and analysis, decision to publish, or 1336 1337 preparation of the manuscript
- Competing interest statement 1338
- NL is an academic editor at PLOS Medicine, received the grant funding from the organisations 1339
- declared above, is a member of the Swiss National COVID-19 Science Task Force, and is on the 1340
- scientific board of Sefunda, a start-up company that develops point-of-care diagnostics for sexually 1341 transmitted infections. 1342
- 1343 DBG receives funding from the organisations declared above.
- 1344 AMI, LH, HI receive salary support from the grants to NL from the Swiss National Science Foundation 320030 176233, and/or European Union H2020 101003688. 1345
- 1346 **Supporting Information**
- S1. PRISMA Checklist 1347
- 1348 S1 Text. Search strings
- 1349 S2 Text. Risk of Bias tool
- 1350 S1 Appendix. Data extraction forms
- 1351 S2 Appendix. Analysis of other systematic reviews on asymptomatic SARS-CoV-2
- 1352 S1 Table. Studies included in version 3.0 and excluded in version 4.0 of the living systematic review
- S2 Table. Characteristics of studies reporting on proportion of asymptomatic SARS-CoV-2 infections 1353 (review question 1 and question 2) 1354
- 1355 S3 Table. Location of studies contributing data to review question 1
- 1356 S4 Table. Subgroup analysis according to risk of bias
- S5 Table. Characteristics of mathematical modelling studies 1357
- S1 Fig. Flowchart of identified, excluded, and included records as of 6 July 2021 1358
- 1359 S2 Fig. Forest plot of proportion of people with asymptomatic SARS-CoV-2 infection, stratified by 1360 study design.

- 1361 S3 Fig. Risk of bias assessment of studies in question 1 and 2
- 1362 S4 Fig. Forest plot of proportion of people with asymptomatic SARS-CoV-2 infection by date ofpublication.
- 1364 S5 Fig. Assessment of credibility of mathematical modelling studies.